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CHAPTER 1 :  INTRODUCITON AND DEFINITIONS 
INTRODUCTION 
The average annual rate of squamous cell carcinoma of the upper aerodigestive tract 
in Belgium is 22.4/100,000. It accounts for approximately 3.5% of all malignant 
neoplasms in our country (1). World-wide more than 500,000 new cases are 
registered annually and this incidence shows a tendency to increase (2,3). Although 
treatment protocols of head and neck cancer have improved considerably over the last 
20 years, the overall survival rate has only marginally increased (4). Though better 
methods of controlling local and regional disease have been developed, the 
occurrence of second primary tumours has become increasingly responsible for the 
lack of progress (5,6). 
«So ist wohl auch die Annahme nicht auszuschliessen, dass, bei einem Individuum 
sich zweimal im Leben Carcinom entwickeln kann, wenn das erste mal radikale 
Heilung durch die Operation erzielt worden war.» So concluded Theodore Billroth 
his report, more than a century ago, of what were probably the first clearly 
documented examples of multiple primary malignant neoplasms (7). More than 60 
years later, in 1932, Warren and Gates reviewed 1259 patients from the world 
literature (7). In their report they proposed the classification criteria for second 
primary tumours that are at present still used (see Def.2, below). Since then, many 
studies have been published reporting a rising incidence of multiple primary tumours. 
By careful and detailed histological studies, Slaughter and co-workers demonstrated 
in 1953 the phenomenon of multicentricity in patients with squamous cell cancer of 
the oral epithelium. They realised that the entire epithelial surface at risk is exposed 
to repeated carcinogenic insults (e.g. from tobacco use) and suggested that such 
exposure increases the likelihood that multiple, independent premalignant and 
malignant foci will develop in the exposed epithelium (8). Squamous cell carcinoma 
of the oral cavity is then the end result of a process of «field cancerization». This led 
to the concept of a large zone of mucosa at risk, the so-called «condemned mucosa». 
Better understanding and greater awareness led to increasing incidence reports. The 
occurrence of multiple primary carcinomas is especially important in head and neck 
cancer. Ogden et al. showed that patients with head and neck cancer have a greater 
risk of a second primary malignancy than any other group of patients with cancer (9). 
Multiple primary malignancies, once considered a medical rarity, are today 
considered a common problem in head and neck oncology. 
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DE FINITIONS 
I .  Criteria 
It is essential to define the criteria used to diagnose multiple primary malignancies in 
order to differentiate a second primary lesion from a primary tumour with metastasis. 
In 1932, Warren and Gates redefined the original criteria of Billroth as follows (7): 
1. Each tumour must be clearly malignant on histological examination. 
2. Each tumour must be geographically distinct and not connected by submucosal or 
intraepithelial neoplastic changes. 
3. The possibility of the second tumour representing a metastasis must be excluded. 
The fulfilment of criterium 2 is not always evident. When the separate foci have 
significant histological differences, the diagnosis of separate primary cancers is 
appropriate. But when both tumours have the same histology, other microscopical 
findings are important. Probably the most important histological observation of a 
separate primary infiltrating carcinoma is identification of its origin from the 
overlying epithelium. The observation that the invasive carcinoma arises from an 
overlying epithelium that demonstrates a transition of carcinoma in situ to invasive 
carcinoma is proof for a primary tumour. Often, the pathologist can differentiate a 
metastatic lesion from a separate primary tumour by microscopic examination. Still, 
in many cases, only probability diagnosis can be made. To overcome this difficulty, a 
slight modification of the second criterium was proposed by Hong et al.: «A second 
primary tumour of the same histologic type as the first must be separated from it by 
more than 2 em of normal epithelium or must occur at least three years after the 
diagnosis of the first primary tumour» (10). 
About criterium 3, some remarks have to be made. Distinguishing a second primary 
lung tumour from a metastatic lung lesion is not always clear-cut. When there are 
multiple lung lesions, the likelihood of a metastasis is high. Cahan stated that if a 
patient had or has a squamous carcinoma elsewhere in the body, a solitary lung lesion 
has a 3 5 to 1 chance to be a separate primary lung cancer rather than a single 
metastasis ( 11). Important considerations are: 
1. The magnitude and aggressivity of the primary tumour: as a rule a solitary tumour 
in the lung can be regarded as a primary malignancy if the head and neck index 
tumour is/was classified as T1 or T2, without lymph node metastasis or without signs 
of local or regional recurrences (12). 
2. The time interval between the detection of the primary tumour and the appearance 
of the lung lesions: 93% of the distant metastasis appear in the first two years 
following the detection of the primary tumour. The longer the time interval, the more 
likely it is a second primary lung tumour. 
3. The localisation of the lung tumour: endobronchial versus parenchymal. Metastatic 
lung lesions are more frequently encountered in the lung parenchym. 
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Again Hong et al. suggested a more rigorous criterium: «Any new tumour of the 
lungs must be solitary and histologically distinct from the primary tumour, unless it 
occurs three or more years later» (I 0 ) . 
2. Classification according to time of appearance 
The temporal sequence of the appearance of multiple tumours was emphasised in 
1964 by Moertel, who formulated the criteria for synchronous and metachronous 
lesions (13). 
The index tumour is defined as the first head and neck tumour diagnosed. 
Simultaneously developing tumours are lesions which develop at the same time and 
are diagnosed at the initial presentation. The more malignant or more life-threatening 
tumour is usually called the «first» or «index» tumour. 
Synchronous tumours include those that present either simultaneously or within a 6 
month period of identification of the original tumour. 
Metachronous tumours are identified as tumours diagnosed more than 6 months after 
the index tumour. 
3. Classification according to localisation 
Multiple primary tumours can be categorized according to localisation. Kapsinow, in 
1962, proposed the following categories (14): 
Multicentric tumours: tumours occuring in the same organ 
Systemic tumours: tumours localized in anatomically or functionally allied organs of 
the same system e.g.the combination of a laryngeal and a lung tumour. 
Paired tumours: tumours localized in bilateral organs e.g. bilateral tonsil, ovary, 
breast and testicular tumours. 
Randomly localized tumours: coincidental associated tumours e.g. laryngeal and 
bowel carcinomas. 
A fifth category was proposed by De Vries (15): 
Etiologically related tumours: tumours caused by a shared etiology e.g. the 
combination of laryngeal and bladder cancer, which are both related to the use of 
tobacco. 
ETIOPAT HOGENESIS 
1. Concept of multicentricity 
The concept of multicentric origin of malignant neoplasms was already expressed in 
1944 by Willis who stated: 
«In human as in experimental carcinogenesis the effective stimuli are applied, not to 
4 
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one cell or one small group of cells, but to a more or less extensive area of epithelial 
tissue. All the epithelium in that area is acted upon similarly, though of course usually 
not equally. Neoplasia will commence where the stimuli have been maximal, but the 
neoplastic response will later be manifested by neighbouring tissue that was subjected 
to the same original stimuli» (16). 
Carcinogenesis is not an isolated biological event. It is the result of specific 
carcinogenic influences acting on susceptible tissue for a sufficient amount of time to 
start irreversible anaplastic changes in the reproductive pattern of the cells. After a 
variable amount of time, multiple areas of in situ carcinomatous change will begin at 
the point of maximum carcinogenic stimulus. Multicentricity is known in all organ 
systems albeit with varying frequency. In 1977, Moertel reported on the patient data 
collected at the Mayo Clinics. Multicentric tumours at a macroscopic level could be 
detected for different sites with a frequency varying from 2.2% for stomach cancer to 
58% for vulva and vaginal cancer with 8.7% for oral cancer (17). At microscopic 
level the problem is even more impressive. Table 1 shows anatomo-pathological 
studies in which, during careful histological examination of macroscopic normal 
tissue in the vicinity of invasive cancer, separate areas of carcinoma in situ or early 
invasive cancer were found. The incidence of multicentricity in these studies varies 
between 20% for cancer of the vulva and 93% for oral cavity cancer. 
Table 1: Frequency of multicentric tumours in tissue studies of patients with an 
invasive tumour in the same organ (after Moertel, Cancer 1977;40:1786-92) 
Author, Year Site % 
Green et al. 1958 Vulva 20 
Collins and Gall 1952 Stomach 22 
Skinner et al. 1974 Bladder 56 
Auerbach et al. 1957 Lung 89 
Slaughter et al. 1946 Oral cavity 93 
Multicentric, systemic and paired tumours are often etiologically related. The 
observation that all stages of carcinogenesis may be present not only in one system 
but also in different areas of related systems subjected to the same carcinogens and 
co-carcinogens (promoting factors) has led to the concept of a larger multicentric 
zone. Indeed, it seems logical that the oral area, the oesophagus and the 
tracheobronchial area, as they are exposed to surface-contact carcinogens, will 
respond by forming multiple primary neoplasms, either simultaneously or 
metachronously. The mere existence of one tumour implies an increased 
susceptibility to the development of other malignant neoplasms in the same or related 
systems. 
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Information on the genetic basis of a possible multistep process of carcinogenesis is 
accumulating. Tumour initiation starts with somatic mutations, causing an altered 
expression of specific genes involved in proliferation and differentiation of squamous 
epithelium (18). Several groups are currently involved in the elucidation of these 
steps and the associated genetic and/or phenotypic alterations (19,20,21). Mutations 
in the p53 tumour suppressor gene represent a genetic alteration occurring during the 
evolution of premalignant lesions to malignancies of the upper aerodigestive tract. 
The discordant p53 mutations in second primary cancers arising in patients with 
primary epithelial cancer of the upper aerodigestive tract suggest that these cancers 
arise as independent events (22,23,24). 
2. Etiologicalfactors 
Tobacco and alcohol 
Tobacco and alcohol are established risk factors in the development of squamous cell 
carcinoma of the head and neck. The aromatic hydrocarbons of tobacco are known 
carcinogens to the upper and lower respiratory tract as well as to the digestive and 
genitourinary systems. Experimental evidence suggests a role for tobacco in the 
molecular progression of squamous-cell carcinoma of the head and neck (p53 
mutations at nonendogenous mutation sites) (25). Increasing intensity and 
prolongation of smoking is associated with an increased relative risk (26,27). Quitting 
smoking is asociated with a sharply reduced risk of cancer of the head and neck, with 
no higher risk detected among those who have quit for 10 years or more (26). 
Epidemiological and experimental data support the existence of an interaction 
between alcohol and mutagens (eg cigarette smoke condensate) and suggest that 
alcohol has co-carcinogenic properties (28,29). Ethanol, though itself not a mutagen, 
exerts its genotoxic effect by blocking repair of genetic damage induced by mutagens 
(28). Some studies, however, have shown that there is an independent and different 
contribution to the incidence of head and neck cancer for alcohol consumption (30). 
No consistent findings have been found on the risk of different types of alcohol, such 
as hard liquor, wine and beer, related to the relative risk of developing head and neck 
carcinoma (31). Alcohol is also believed to cause a debilitated status in the host 
through malnutrition and immune surveillance suppression (32). 
Some studies support the hypothesis of a carcinogenic effect of alcohol and tobacco 
via a direct contact mechanism: tobacco smoking is more strongly associated with 
lesions in sites heavily exposed to inhaled smoke, whereas alcohol consumption has 
a stronger effect on structures belonging to the «food channel» (30,33). A dose­
response relationship can be demonstrated for tobacco smoking as well as for alcohol 
consumption (26,33,34,35). 
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Irradiation 
Reports on the association between irradiation and the development of metachronous 
tumours have been conflicting. Most authors agree that low dose radiotherapy 
administered for benign conditions augment the incidence of head and neck 
neoplasms, mostly after an interval of 30 years. There are, however, conflicting 
reports concerning the risk for development of a second primary tumour after a 
therapeutic irradiation for a malignant neoplasm of the head and neck. Some studies 
have shown that radiotherapy reduced the local incidence of new tumours by 
destroying microscopic tumours (36,37). Others report an increased risk of cancer in 
areas that have received therapeutic irradiation (32,34). Wagenfeld analysed his cases 
of stage T l  glottic carcinomas for the frequency of late recurrences and/or second 
primaries in the larynx following radiotherapy (38). He concluded that late recurrence 
and/or second primary in the larynx was not a significant problem following 
radiotherapy for laryngeal carcinoma. 
Host factors 
Copper et al. (39) and Bongers et al (40) showed in an epidemiological case-control 
study that a genetic predisposition is an independent risk factor for head and neck 
carcinogenesis. They demonstrated that first degree relatives of head and neck 
squamous cell carcinoma patients have a relative risk of 3 .5 to develop a head and 
neck tumour. Cytogenetic studies, measuring the bleomycin-induced damage in 
cultured lymphocytes, support the existence of a constitutional risk factor for head 
and neck carcinogenesis (41,42,43,44). Variability in genetically determined 
detoxification pathways of procarcinogenic components of cigarette smoke by 
specific enzyme systems (eg glutathione S-transferase and cytochrome p-450 
enzymes) may be important in neoplastic transformation (18). Gallo et al. showed 
that chromosomal analysis of head and neck cancer patients (HNCPs) with multiple 
tumours demonstrated a higher sensitivity to clastogens than of H.NCPs with a single 
cancer (45). This increased mutagen sensitivity, as shown for H.NSCC and especially 
HNSCC patients who develop a second primary tumour (SPT), could result from an 
inherited predisposition (41 ,42). 
There is still a lot of discussion about the role of the immune system in the aetiology 
of second primary tumours. Some studies suggest that cancer patients have a 
generalised immunologic incompetence (32). An important observation was made by 
Shikhani et al. who found that patients, who have received radiotherapy, show 
significant decreases in total lymphocytes, T cells, helper cells, and helper/suppressor 
ratios (46). This long lasting radiation-induced immune depression, alone or in 
combination with the immune depression due to tobacco products, may have 
relevance to the development of second primary tumours in the head and neck. 
Immunologic incompetence suggests an increased risk of cancer not only in the 
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region of the bead and neck, but in other tissues as well. Further studies are required 
with special emphasis on detecting high-risk groups by means of HLA or 
immunoglobulin typing. 
Occupational factors 
Occupational exposure to sulphuric acid, coaUtar products, mineral vitreous fibres, 
thermoplastic resins, pesticides, paint and other chemicals is a proven etiological 
factor in bead and neck cancer (47,48). Concerning asbestos, contradictory reports 
have been made. Stell and McGill found an association between laryngeal carcinoma 
and asbestos exposure (49), while Parnes could not demonstrate asbestos as an 
etiological factor but only as an irritant (50). More detailed epidemiological studies 
which are adjusted for alcohol and cigarette consumption are necessary to investigate 
a possible association between occupational agents and head and neck cancer. 
Nutritional factors 
Epidemiological data suggest an inverse association between the consumption of 
fruits and vegetables and the incidence of head and neck cancer (51,52). From 
epidemiological and animal studies it became evident that some micro-nutrients are 
protective against cancer. Examples are selenium, vitamin E, and vitamin A (53). 
Retinoids, the synthetic and natural vitamin A derivatives, may play a major role in 
the prevention of progression of premalignant lesions that are often found in head 
and neck carcinoma patients. 
AIMS OF THE ST UDY 
Most early reports on multiple primary cancers of head and neck were retrospective 
studies reporting incidences varying from 2% to 30%, with an average of 5%. This 
knowledge resulted in prospective studies looking for synchronous and metachronous 
multiple primary tumours. As was expected, in prospective studies incidences of 
synchronous tumours were even higher. To have a better idea of the magnitude of the 
problem, we performed a meta-analysis on data from 25 studies reporting 
synchronous and metachronous malignancies in head and neck cancer patients 
(Chapter 2). We wanted to answer the following questions: 
1. What is the prevalence of synchronous and metachronous second tumours? 
2. Does the prevalence of multiple primary tumours depend on the site of the index 
tumour? 
3. Does the site of the second tumour depend on the site of the index tumour? 
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Demographic variations in patterns of head and neck malignancies imply that the 
incidence of multiple primary tumours published in literature cannot unquestionably 
be extrapolated to different countries. Therefore we conducted a prospective study of 
patients with head and neck malignancies undergoing treatment and follow-up at the 
Department of Otorhinolaryngology at the University Hospital of Ghent. 
In Chapter 3 the epidemiological data of the 127 patients are outlined. 
In Chapter 4 we describe the results of the panendoscopic procedure used as a 
screening for synchronous primary tumours. We wanted to answer the following 
questions: 
1 . What is the incidence of simultaneous primary tumours of the head and neck in our 
population? 
2. Is it necessary to perform a panendoscopic procedure in every head and neck 
cancer patient as a screening procedure for simultaneous primary tumours? 
In Chapter 5 we evaluate the usefulness of the rigid bronchoscopy and bronchial 
washings in detecting a synchronous primary lung tumour in the presence of a 
squamous cell carcinoma of the head and neck 
In Chapter 6, we report the results of the follow-up of the 127 patients. We 
specifically looked for: 
1. The incidence of synchronous and metachronous second primary tumours 
2. The implications of the appearance of a second primary tumour on survival. 
Finally, future perspectives concerning follow-up and treatment of head and neck 
cancer patients are discussed. 
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ABSTRACT 
Head and neck cancer is often associated with second primary neoplasms, the 
incidence varying from 5% to 30%. 
A meta-analysis was performed on data from 25 studies reporting synchronous and 
metachronous second malignancies in head and neck cancer. 
The overall prevalence of multiple primary tumours is 15.2%. The prevalence of 
synchronous second primaries in prospective studies is higher than in retrospective 
studies (9.05% vs 4.5%). Site analysis shows that the prevalence and the localisation 
of second malignant tumours depended on the site of the index tumour. Oral cavity 
cancer has the highest prevalence of second malignant tumours. Head and neck 
second primaries were most common in this group. Laryngeal cancer patients carried 
the highest risk for the development of a second primary in the lung. About half of 
the second primaries were detected within two years after the detection of the index 
tumour but they continued to appear even after 5 years. 
It can be concluded that multiple primary tumours are an important phenomenon in 
head an neck cancer. If we want to improve the long-term survival of these patients 
we must address to this problem. 
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INTRODUCTION 
Treatment protocols in head and neck cancer patients have improved considerably 
over the last 50 years. Continuing advances in reconstructive surgery diminish the 
morbidity and allow larger tumour resections. When these surgical interventions are 
combined with radiotherapy, and eventually chemotherapy, there is an improvement 
in both local and regional tumour control. Unfortunately, there is only a modest 
impact on survival. Loco-regional recurrence is still the major cause of death (1), but 
the occurrence of new tumours in the same patient, and the development of distant 
metastases become also important in jeopardizing the survival of head and neck 
cancer patients (2,3,4). The overall incidence of distant metastases has not changed 
much, but whereas distant metastases were almost always preceded by neck 
metastasis in the past, this is not always the case anymore, thanks to more effective 
local and regional treatment (2). But even if we could develop a strategy capable of 
providing a 100% cure rate, the gain in survival would remain relatively modest 
because some patients will develop new cancers. 
In 1860, Billroth was the first to draw attention to the occurrence of more than one 
cancer in a patient. Seventy two years later, in 1932, Warren and Gates published an 
extensive review on the subject (5). They formulated three criteria that must be 
fulfilled for a tumour to be considered as a second primary tumour. These criteria are 
still valid : 
I) Each tumour must be clearly malignant on histological examination. 
2) Each tumour must be geographically distinct and not connected by submucosal or 
intraepithelial neoplastic changes. 
3) The possibility of the second tumour representing a metastasis must be excluded. 
In 1964, Moertel classified the tumours according to time of appearance (6) : 
- index tumour: the original presenting tumour. 
- simultaneous tumours: tumours that develop at the same time and are diagnosed at 
the initial presentation. 
- synchronous tumours: tumours detected within a 6 month period of identification of 
the index tumour. 
- metachronous tumours: tumours diagnosed more than 6 months after the index 
tumour. 
The incidence of second malignant tumours in head and neck cancer is now a well 
documented phenomenon, being as high as 5-30%. Clinical evidence has 
accumulated to support the «field cancerization» concept or «condemned mucosa» 
syndrome, originally formulated by Slaughter in 1953 for cancer of the oral cavity 
(7): all stages of carcinogenesis may be present in different areas of the aero-digestive 
tract subjected to the same carcinogens and co-carcinogens, not only simultaneously 
but also metachronously. The mere existence of one tumour implies an increased 
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susceptibility to the development of other malignant neoplasms in the same or related 
systems. More recently, information on the genetic basis of a possible multistep 
carcinogenesis is accumulating (8). Increased sensitivity to carcinogens, as detected 
by clastogen-induced chromosome fragility, increases the risk for developing 
tumours (8). More evidence for the multistep carcinogenesis theory is recently 
provided on molecular basis. Mutations in the p53 tumour suppressor gene represent 
a genetic alteration occurring during the evolution of a premalignant lesions to 
invasive cancer of the upper aerodigestive tract. The discordant p53 mutations in 
second primary cancers arising in patients with primary epithelial cancer of the upper 
aerodigestive tract suggest that these cancers arise as independent events (9,10,11). 
To have a better idea of the magnitude of the problem, we performed a meta-analysis 
on data from 25 studies reporting synchronous and metachronous malignancies in 
head and neck cancer patients. We wanted to answer the following questions: 
- What is the prevalence of synchronous and metachronous second tumours? 
- Does the prevalence of multiple primary tumours depend on the site of the index 
tumour? 
- Does the site of the second tumour depends on the site of the index tumour? 
We conducted an extensive literature review in which published material was 
included according to the following criteria : 
1. The primary topic of the study was second malignancies in head and neck cancer. 
2. Data were available for synchronous, metachronous, or overall rate of second 
primary tumours. 
3. Warren and Gates' definition of second primaries was used. 
4. The index tumours could be separated into the four principal regions, i.e. the 
larynx, oropharynx, hypopharynx, or oral cavity. Nasopharyngeal and sinus cancers 
were excluded. Second primaries were identified by site, including aero-digestive 
tract and distant locations. 
5. The number of second primaries appearing by 1 year, 2 years, and more than 5 
years had to be expressed as percentages of the total second primaries detected. 
Twenty five studies were appropriate for inclusion (Table 1a and 1b). This gave us a 
total of 2 1,018 patients of which 10,670 were exclusively laryngeal cancer patients. 
Twelve of the 25 studies were prospective and were analysed separately for 
prevalence. 
For site analysis, we used 13 studies for laryngeal cancer ( 10,670 patients), 7 studies 
for oral cavity cancer (3,619 patients), 4 studies for oropharyngeal cancer ( 1,845 
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patients), and 6 studies for hypopharyngeal cancer (1 ,365 patients). 
For the follow-up analysis, 7 studies qualified for inclusion. 
Table 1 : Individual studies used for prevalence 
la. Retrospective 
First Author year l.ocat.ioo n % second prime 
( reference synch. metach total 
Gluckman ( 40 ) 7 9  Cincinnati 1 6 2  9.2 % 
Weaver (41 ) 7 9  Michigan 1 24 1 3 % 7% * 2 0 % 
Me Guirt ( 42 ) 8 2  NorthCaro1ina 1 0 0  1 8 % 
Atkinson ( 43 ) 8 2  Michigan 2 7 1  1 0 . 3%1 5 . 1% 2 5 . 5% 
Hordijk ( 36) 8 3  The Netherlands 1 0 0  2 %  
Atkins (44) 84 Philadelphia 4 5 1 2 . 5% 5 . % 9 . 5% 
De Vries (45 ) 8 5  The Netherlands 1 0 0  1 6% 
Leipzig(46) 8 5  Colorado 3 84 8 . 9% 
Lau (47 )  8 6  Bong Kong 1 0 5  8 . 5% 
Schuller ( 48 ) 8 6  Ohio 5 3  1 1 . 3% 
Parker ( 49 ) 8 8  Chicago 2 0 8  7 . 2% 
Hordijk ( 5 0 )  8 9  The Netherlands 14 1 1 .  4% 
n: index tumour cases synch. = synchronous metach. = metachronous 
1 b. Prospective 
FirstAuthor year location n % second prime 
( reference synch. me tach total 
Vrabec ( 3 0 ) 7 9  Pennsylvania 1,5 1 8  2 .7 8 . 8  1 1 . 5  
Weichert ( 3 1 )  7 9  Cincinnatti 8 2 5  2 . 3  4 . 2  6 . 5  
Shapshay ( 32 ) 7 9  Boston 1 5 0  1 4 0 0% 5 1 9  
Cohn (33 ) 8 0  Michigan 267 9.4 7 . 1  16 . 5  
Maisel ( 34 )  8 1  Minnesota 44 9 8 0 0 % 9 . 8  17 . 8  
Deviri (35 ) 8 2  Israel 1,66 0.8 4.2 5 
Gluckman ( 1 9 )  8 3  Cincinnati 5,3 37 5 0 0 % 8.5 14 
Hordijk( 36) 8 3  The Netherlands 9 7 0  2.2 16.8 1 9  
Grossman (37 ) 8 3  Milwaukee 6 9 6  5.6 1 0. 8  16 .4 
Shons ( 3 8 )  8 5  Minnesota 4 0 5  3 . 2  9 . 6  1 3  
Shikhani ( 14) 8 6  Baltimore 1,961 4.5 5 . 2  9.7 
Larson ( 1 2 )  8 8  Minneapolis 8 7 5  8 . 2  1 5.4 24 
Haughey ( 3 9 )  9 1  StLouis 3,7 0 6  2 . 5 1 0 . 3  1 2 . 8  
n :  index tumour cases sync h. = synchronous 
metach. = metachronous *:only 2 years of follow-up 
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STATISTICS 
Nonparametric tests were used for comparing site-specific rates within and across studies with 
correction for sample size. A level of p<O .05 was regarded as significant The analysis was done 
with the help of the Department of Medical Informatics and the statistical package SPSS was 
used. 
RESULTS AND DISCUSSION 
1. Prevalence of multiple primary tumours in head and neck cancer. 
We found an overall median prevalence of second primary tumours of 15.2%. The 
median prevalence for synchronous second primary tumours was 7.2%. The median 
prevalence for metachronous second primary tumours was 8.6% (Table 2). 
A possible source of bias in the calculation of the overall prevalence was the high 
proportion of laryngeal cancer patients (10,670 patients) in the total head and neck 
cancer population (21 ,0 18). Further analysis showed that this index site has a lower 
rate of second primary formation than other head and neck sites. 
Table 2 : Meta-Analysis : Prevalence data for synchronous, metachronous and overall 
multiple primary tumours 
Parameter Synchronous 
N ( n )  2 5  ( 2 1 , 0 18 ) 
n' 9 1 9  
Mean 7 . 1% 
Mean ( weighted ) 4 . 4% 
I Median 7 . 2% 
Range 0 . 8% - 1 8% 
N: number of studies n: number of patients 
Metachronous 
1 6  ( 1 9 , 6 6 5 ) 
1 , 748 
9 %  
8 . 3% 
8 . 6% 
4 . 2% - 1 6 . 8% 
n ': number of patients with a second primary tumour 
Overall 
1 6  ( 19 , 6 6 5 ) 
2 , 5 6 
1 5 % 
1 2 . 2% 
1 5 . 2% 
5% - 2 5 . 5% 
The prevalence rates for synchronous and metachronous multiple tumours varied 
between the different studies. The highest synchronous prevalence was found in a 
study by McGuirt, which was a prospective study in which panendoscopy was 
performed by a trained otolaryngologist for the detection of a synchronous double 
tumour (42). Separate analysis of the 12 prospective studies revealed a prevalence of 
9.05% for synchronous double tumours; the prevalence in the retrospective studies 
was only 4.5% (Table 3). Although this difference only approached significance 
assessed by a Mann-Whitney U-test (p=0.08), it confirms a general tendency that the 
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prevalence of synchronous multiple tumours is higher in prospective studies, because 
there is an active search for synchronous multiple tumours e.g. with a panendoscopic 
screening protocol. 
Table 3 : Meta-Analysis : Median prevalence for synchronous second primaries in 




p = 0.087 (Mann-Whitney U-tesl) 
N: number of studies 
N 
2 5  
1 2  
1 3  
median 
7 . 2% 
9 . 0 5% 
4 . 5% 
The overall prevalence of metachronous tumours was 8.6%. As most of the data were 
collected from retrospective studies, the true incidence is probably still 
underestimated because of patients lost in follow-up or treated elsewhere. There also 
is a wide range in the rates of prevalence for metachronous multiple tumours between 
the different studies. The reasons for this are multiple. Some studies used a Tumour 
Registry for the collection of their data, which explains the large proportion of second 
tumours not belonging to the aerodigestive system. In other studies, the prevalence 
data were the result of an intensive clinical surveillance of a group of patients at risk, 
by a single group of physicians. Some studies were conducted by Radiation Therapy 
Oncology Groups that probably have a selected cancer population under treatment. 
Racial and regional differences could also be of importance in determining the 
prevalence of multiple primary tumours. Environmental or occupational factors e .g .  
exposure to asbestos , may attribute to the development of  cancer. Also smoking and 
drinking habits show racial and regional differences . 
Another important consideration is that the prevalence of multiple primary tumours 
depends on the site of the index tumour. In many studies, no information was given 
about the site distribution of the index tumour population. Even less information was 
given concerning the stage distribution. This is important because patients with T l ­
T2 stage tumours are more likely to be cured from their fust tumour and therefore are 
more likely to develop a second tumour (12). So the site and stage distribution in the 
study population determines the prevalence of multiple primary tumours . All these 
factors contribute to the differences noted in the prevalence of multiple primary 
tumours. Nevertheless we can conclude that the occurrence of multiple primary 
tumours is an important observation. The overall median prevalence of 15 ,2% 
suggests a sufficiently large yield to make screening worthwhile. Prospective studies, 
where an active search is performed e.g .  by means of a panendoscopic procedure 
report a higher prevalence of synchronous multiple primary tumours. In the future 
this would equally apply to the prevalence of metachronous multiple tumours when 
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in the follow-up of this population at risk a screening protocol for the early detection 
of second tumours will be used. 
2 .  Site analysis of second malignant tumours by index tumour site . 
For the site analysis, we classified the index tumours according the ICD-0 in 
laryngeal cancer, oral cavity cancer, oropharyngeal and hypopharyngeal cancer. The 
second tumours were grouped into four categories according to their appearance in 
the lung , in the oesophagus , in the head and neck and elsewhere in the body (Table 
4). The overall prevalences for second primaries at the four index sites differed with 
a trend towards a higher prevalence for the oral cavity versus other sites (Table 5). 
This difference was, however, not statistically significant . 
Table 4 : Site analysis of second malignant tumour by index tumour site 
Index tumour N n n' Lung Esophagus H & N 











3 0  
1 0 , 671 , 160 ( 1 0 445 ( 38 . 4 ) 53 ( 4 . 6 )  215 ( 1 8 . 5J27 ( 3 6 . 1  
3 , 6 1 9  5 6 1  ( 15 . 5 J l4 ( 2 0 . 3 ) 52 ( 9 . 3 )  231 (41 . 2 � 5 2  ( 27 . :  
1 , 845 241 ( 13 . 1 )35 ( 14 . 5 )  14 ( 5 . 8 )  117 (48 . 5 �5 ( 27 . 0  
1 , 3 6 5 1 87 ( 13 .7 )4 0 ( 2 1 .4 )  14 ( 7 . 5 )  73 ( 3 9 . 0 ) 49 ( 2 6 . 2  
17 , 5  2 , 149 ( 12 634 ( 2 9 . 5 )1.33 ( 6 . 2 )636 ( 2 9 . 6� 9 3  ( 3 2 . :  
N: number of studies 
n: number of patients with an index tumour 
n ': number of patients with a second primary tumour 
H&N: Head and Neck 






p = 0.52 (Kruskal-Wallis test) 
Median 
12 . 9  
17 . 4  
14 .4 
13 . 0  
Within sites for laryngeal and oral cavity index tumours , the different prevalences of 
second primary tumours by site were statistically significant as judged by a Friedman 
test performed on transformed , non parametric data (Table 6). For laryngeal primary 
cancer, there was a strong preference for the lung as second primary site , followed by 
the head and neck (p=O.OOOl ) .  We also noted a high prevalence of second primary 
cancer outside the aero-digestive tract. A possible explanation is that laryngeal cancer 
is primarily a disease of the sixth and seventh decade (13) .  Also the prognosis is 
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somewhat better. So patients have the opportunity to develop second tumours in 
unrelated organs. In the oral cavity there was a strong statistically significant 
predominance of second primaries in the head and neck region, followed by the lung 
(p=0.005) .  We also noted in this group of oral cavity cancer an important percentage 
of oesophageal tumours. Patients with oral cancer are notoriously known for 
excessive use of tobacco and alcohol which often gives rise to oral field cancerisation. 
As it is impossible to remove all of the exposed mucosa, second and third primaries 
are often observed in this same area. Although it was not statistically significant 
because of the small numbers of studies available, the same was true for the 
oropharyngeal and hypopharyngeal index tumour group (p=0.09). 
Table 6 : Meta-Analysis : Prevalence of second primaries by site (lung, esophagus, H&N 
and other ) for the different subsites of the index tumour (laryngeal, oral cavity, oropharynx 
and hypopharynx ) 
Second prim. Lung Oesophagus H&N Other 
Indexsite 
Larynx 5 . 1 9% 0 .  34% 2 . 34% 4 . 46% p = 0 . 0 0 0 1  ( N=l 
Oral Cavity 3 . 2% 1 .  43% 9 . 2% 2 . 63% p = 0 . 0 05 ( N=7 )  
Oropharynx 2 . 4 8% 0 . 8% 5 . 1 7% 3 .  7 1% p = 0 .  09 ( N=4 ) 
Hypopharynx 2 . 8 8% 0 . 62% 6 . 1 2% 2 .  4 1% p = 0 . 0 9 ( N""6 )  
Overall 3 . 2 9% 0 . 62% 4 . 2 9% 3 . 0 5% p < 0 . 00 0 1  ( N=3 
N: number of studies 
p : according to Friedman test 
Based upon these findings, we can state that patients with an oral cavity index tumour 
have a higher overall prevalence of second primary tumours. Secondly, the site of 
development of the second primary tumour is related to the site of the index tumour. 
A tumour which has risen in the digestive tract suggests an increased susceptibility of 
the entire upper digestive tract, while a similar susceptibility to tumour formation 
seems to exist along the respiratory tract axis. 
3. Analysis of second primary tumours during follow-up. 
We were able to find comparable data regarding intervals before detection of second 
primary tumours in 7 studies . The cumulative incidence of second primaries 
appearing by 1 year was 25% to 60% and by 2 years 43% to 74%. After 5 years, 
between 7% and 42% of the second primaries still remained to be detected (Table 7). 
When we looked at the appearance of second primary tumours in a laryngeal index 
tumour population, the cumulative range appearing by 1 year was 1 3% to 55% and 
by 2 years was 21% to 78%. After 5 years 0% to 47% of second primary tumours 
remained to be detected (Table 8). After 5 years, up to 38 % of the second tumours in 
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Table 7 : Incidence of second primary tumours in time course 
Author n n '  < 1 year < 2 year > 5 years time of follow-u 
(reference) cum ( % )  cum (%) ab ( % )  
Haughey ( 3 9 ) 3 , 7 0 6  5 2 8 1 8 6  ( 35 )  225 ( 4 3 2 2 3  ( 4 2 ) mean 6 . 3  y 
Larson ( 12 )  8 7 5  2 0 7  9 5  ( 4 6 )  1 3 2  ( 6 4 )  3 4  ( 16 ) 10 year retro 
Vrabec ( 3 0 )  1 , 5 1 8  1 1 4  5 1  ( 45 )  6 8  ( 6 0 ) 2 6  ( 23 ) 9 y retro 
Hordijk ( 3 6 )  1 , 1 4 8  1 9 4  5 8  ( 3 0 )  1 0 1  ( 52 58 ( 3 0 ) 22 y retro 
Shikhani ( 14 ) 1 , 9 6 1  1 9 0  1 1 3  ( 60 )  1 4 1  ( 74 13 ( 7 )  10 y retro 
Cohn ( 3 3 ) 2 6 7  4 7  2 7  ( 57 )  34 ( 72 ) 5 ( 1 0 )  not given 
Shons ( 38 ) 4 0 5  5 2  1 3  ( 25 )  2 5  ( 4 8 )  12 ( 23 ) 15 y retro 
n: number of patients with an index tumour 




Table 8 : Incidence of second primary tumours in laryngeal cancer in time course 
Author n n'  < 1 year < 2 year > 5 years time of follow-1 
( reference ) cum ( % )  cum ( % )  ab ( % )  
Haughey ( 3 9 )  1 , 8 6 4  2 0 6  7 6  ( 4 0 )  8 5  ( 4 1 )  9 7  ( 4 7 )  mean 6 . 3  y 
Lundgren ( 51 )  2 9 5 3 2  4 ( 13 ) 7 ( 3 0 )  1 5  ( 4 7 )  minimum 3 y 
Miyahara ( 52 ) 1 , 3 8 9  1 5 1  3 1  ( 2 1 )  s o  ( 3 3 )  7 1  ( 47 )  2 3  y retro 
Strigenz ( 2 9 )  2 1 8  2 3  5 ( 22 )  8 ( 35 )  5 ( 22 )  minimum 7y 
De Vries ( 45 ) 7 4 8  1 0 4  1 0  ( 1 0 )  2 2  ( 2 1 )  1 0  ( 1 0 )  mean Sy 1m 
Shikhani ( 14 ) 4 2 4  5 1  2 8  ( 55 )  4 0  ( 7 8 )  0 ( 0 )  mean 2 . 3  y 
Deviri ( 35 )  1 , 6 6 8 4  1 9  ( 23 )  25 ( 3 0 )  3 2  ( 38 )  not given 
n: number of patients with an index tumour 




the laryngeal index tumour population remained to appear. In the study of Shikhani, 
there was a mean follow-up of only 2.8 mean number of person-years, which 
probably accounts for the zero percentage incidence after 5 years (14). There was a 
statistically significant difference in the cumulative incidence in the global population 
with an index tumour in the head and neck region versus the laryngeal index tumour 
site population and this was true for the cumulative incidence after l year (p=0.008) 
and after 2 years (p=O.OOl )  as assessed by a Mann-Whitney U-test (Table 9) . 
In general we can say that about half of the second primaries appear within 2 years 
after the detection of the index tumour but in laryngeal cancer they tend to appear 
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Table 9 : Meta-Analysis : cumulative incidence of second primary tumours in the overall 
head and neck population and in the laryngeal index tumour population. 
time incidence incidence 
interval (glcbal.) index tumour larynx 
< 1 year 4 4 . 7 4 %  2 1 . 7 4 %  p = 0 . 00 9  
< 2 years 5 9 . 6 5 %  2 9 . 7 6 %  p = 0 . 00 2  
> 5 years 2 2 . 8 1 %  3 8 . 1 0 %  p = 0 .  4 0  
(Mann-Whitney U-test) 
somewhat later in the course of follow-up. In both groups they continue to occur even 
5 or more years after the appearance of the index tumour. 
The risk for second cancer is, in some studies , expressed by annual incidence,  which 
is interesting given the varying follow-up of the different studies included in the 
meta-analysis. Tepperman et al. reported a constant rate of development of second 
primary cancers after oral cancer of 3 .6% per year for at least the first I 0 years of 
follow-up (15). Wagenfeld et al calculated the rate of development of the second 
respiratory tract tumour after glottic carcinoma, which was 1 .3% per year and 
constant with time. No difference was observed between different stages of disease 
(16).  For supraglottic carcinoma, a rate of almost 4% per year was reported (17  ) . 
4. Influence of the second primary tumour on survival 
Finally we looked at the outcome of the patient, once a second primary tumour had 
been diagnosed. Unfortunately, the data of the different studies were unfit for 
statistical analysis. 
CONCLUSION 
Multiple primary tumours are an important phenomenon in head and neck cancer. 
They are partially responsible for the fact that although treatment protocols have 
significantly improved the local and regional control of head and neck cancer, the 
gain in survival remains relatively modest. In general we can say that once a second 
tumour is diagnosed the outcome is poor for most patients. The reasons for this are 
multiple. Firstly there is a high incidence of lung and oesophageal cancer, both of 
which have a poor prognosis (15) .  Secondly, the second primary tumour is often in 
an advanced stage, and at last these second, and sometimes multiple cancers , when 
appearing in the head and neck area, are frequently resistant to further therapy 
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because they often occur in a previously treated field, defying effective treatment 
(16,17). If we want to improve the long-term survival of these patients, we must 
address this phenomenon of multicentricity of squamous cell carcinoma. Primary 
prevention of the development of a second cancer is a desirable objective. Although 
supporting data were not available in this study, other studies have shown that 
patients who continue to smoke are at particularly high risk of second primaries as 
compared to those who stop smoking (18,19,20) . But anti-smoking efforts are, at best, 
only sporadically successful. Furthermore, the occurrence of a second cancer early in 
follow-up suggests that the smoking and drinking habits of most patients prior to the 
appearance of the index tumour play a primary role in further tumour occurrence. 
After quitting smoking, the chance of developing a second primary cancer only 
gradually decreases over the course of years. The mucosa has been primed and retains 
a malignant potential (14) .  An alternate method of prevention would be the use of a 
medication which would prevent the malignant transformation in the mucosa. Much 
work is currently being done to estimate the value of chemoprevention using 
synthetic vitamin A derivatives and N-Acetyl cysteine, but this is still an object of 
clinical research (21 ,22,23,24). The best method of improving the survival in cases of 
multiple primary cancers seems to be early detection so that they can be treated in an 
early stage with, hopefully, an increase of the survival rate. Several reports have 
recommended a more systematic search for additional primary lesions in all patients 
with newly diagnosed head and neck malignancies and have advocated a more 
thorough follow-up of those patients (17 ,25,26,27). We can state that the physician 
engaged in the care of patients with cancer of the head and neck should be familiar 
with the concept of multicentricity. Careful vigilance should be exercised during the 
initial work-up and the follow-up period, not only looking for recurrences of the 
original lesion, but also to actively identify further primary cancers as early as 
possible. At this stage, it is not clear whether screening of head and neck cancer 
patients will improve mortality rates, and even less clear whether they are cost­
effective. Some authors state that each follow-up examination can not be limited to 
the upper aero-digestive tract. The medical oncology literature supports their findings 
that bladder, prostate, colon, and digestive tract tumours (stomach, pancreas) are 
significantly higher in patients with aerodigestive tract tumours . Complete follow-up 
of the head and neck tumour patient should therefore ideally include annual 
evaluation of the urologic and gastrointestinal systems (12). 
Understanding the molecular events underlying the development of second primary 
malignancies may help develop stategies for the prevention and therapy of these 
cancers. 
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ABSTRACT 
A prospective study of head and neck cancer patients was started to gather 
information about topographic and clinical characteristics of head and neck cancer, 
alcohol and nicotine use and the delay in diagnosis. More than half of the patients 
consulted our institution with an advanced stage of disease. As was expected, we 
found a positive association between the size of the tumour and the clinical stage of 
the neck. Concerning nicotine and alcohol use, our results support the hypothesis that 
tobacco smoking is more strongly associated with lesions in sites heavily exposed to 
inhaled smoke, whereas alcohol consumption has a stronger effect on structures 
belonging to the «food channel» and reservoir systems. We found no association 
between delay and tumour stage at diagnosis, but a statistical significant correlation 
was found between the delay and the tumour site. This leads us to conclude that the 
tumour stage at diagnosis is determined mostly by the biology of the tumour. 
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INTRODUCTION 
Treatment protocols of head and neck cancer patients have improved considerably 
over the last 50 years . Advances in reconstructive surgery, combined with 
radiotherapy, and eventually chemotherapy, have improved local and regional tumour 
control. Unfortunately, there is only a modest impact on survival. Loco-regional 
recurrence is still the major cause of death, but the occurrence of new tumours in the 
same patient, and the development of distant metastases also may jeopardize the 
survival of head and neck cancer patients . Therefore, we have to look for different 
ways to improve the outcome of a head and neck cancer patient. A better insight in 
the relationship between nicotine and alcohol use and the localization of the head and 
neck tumour could help us in defining a subpopulation more at risk. Secondly, 
campaigns for early diagnosis are advocated by some investigators because, 
theoretically, delayed diagnosis should inevitably be associated with advanced 
disease. But it is important to know if there is indeed a correlation between the delay 
in diagnosis and the tumour stage of disease. Therefore, we started a prospective 
study in October 1990 at the Department of Otorhinolaryngology of the University 
Hospital of Ghent (Belgium) in head and neck cancer patients to gather information 
about topographic and clinical characteristics of head and neck cancer, alcohol and 
nicotine use and the delay in diagnosis. 
PATIENTS AND 1\:IETHODS 
In a 24-month period, we collected data of 1 27 consecutive patients, referred to the 
Department of Otorhinolaryngology of the University Hospital of Ghent (Belgium) 
with previously untreated, squamous cell carcinoma (SCC) of the head and neck 
region. Patients with a malignancy of the skin, the paranasal sinuses, nasopharynx, 
salivary glands or thyroid were excluded. We used standardized forms to gain 
information about tobacco and alcohol use at the time of diagnosis, the medical 
history concerning previous malignancies and the delay in referral. The use of 
tobacco was expressed in pack year (one pack year = equivalent of smoking one 
package of cigarettes per day during one year) and we made a difference between the 
smokers of filter cigarettes , non-filter cigarettes, pipes and cigars. One cigar and one 
pipeful were assumed to be equal to respectively 4 and 2 cigarette equivalents. The 
intake of alcohol was expressed in units of alcohol per day, assuming that the amount 
of alcohol in a consumption of hard liquor, wine and beer is equal (approximately 10 
g of alcohol per unit) . Drinkers of alcohol were divided into 6 groups according to the 
number of units they drank per day. 
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The site and subsites of the head and neck were defined according to the criteria of 
the International Union Against Cancer (UICC) and the International Classification of 
Diseases for Oncology (ICD-0) (1). In case a tumour involved more than one 
(sub)site, we chose the (sub)site in which the bulk of the tumour was localized. 
Regarding the tumour size and lymph node involvement, all tumours were coded 
according to the latest illCC TNM classification (1). Lymph node involvement was 
decided on clinical examination and the results of the CT scanning. Fine-needle 
aspiration biopsy was routinely done to confirm metastatic lymph node cancer. 
STATISTICS 
Comparison of the different sites was performed using non- parametric tests. For 
qualitative variables such as tumour stage and categories for smoking habits and 
alcohol intake, the chi-square test has been used. For continuous variables we used 
the Kruskal-Wallis and Mann-Whitney U-test. The correlation between delay and 
tumour stage, and tumour stage and clinical stage of the neck, has been expressed 
using the Spearman correlation coefficient (rS). 
To evaluate the role of alcohol and smoking as possible determinants of SCC in the 
various head and neck sites , a case-case study has been performed. As no reference 
group of persons without sec was available as in a case-referent design, relative 
risks (RRs) for SCC at these sites could not be directly estimated. However, the odds 
ratios (ORs) for the association between the different sites of the tumour and the 
alcohol and nicotine abuse could be estimated. These ORs can be equated with ratios 
of RRs. Patients with SCC of the larynx, being the largest subgroup, have been used 
as the reference group. 
By use of the Mantel-Haenszel method (X2-test for stratified 2x2 contingency tables) 
the OR associated with the use of tobacco and alcohol were adjusted for possible 
confounding by each other. Dose-response relationships were assessed to be the 
stratified test for linear trend. As we had no reference population of non-users, 
moderate and heavy users of tobacco ( < 30 pack year versus > 30 pack year) and 
alcohol (< 5 units/day versus > 5 units I day) were contrasted with each other. The 
possibility of a different synergistic effect of the use of tobacco and alcohol and the 
anatomical sites head and neck sec was explored by likelihood ratio tests of 
uniformity of the OR. 
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RESULTS 
1 .  Age and gender distribution 
The group of 127 patients with sec of the head and neck region consisted of 1 1 6  men 
and 1 1  women (male to female ratio : 10 to 1 ) .  The mean age and the median for men 
and for women were 59 and 58 years respectively. The age distribution for the 
different sites is shown in Figure 1 .  The median age for the different sites is 62 years 
for laryngeal carcinoma, 54 years for oropharyngeal carcinoma, 58 years for 
carcinoma of the oral cavity, 61 years for hypopharyngeal carcinoma and 64 years for 
oesophageal carcinoma. 
Fig. 1 : Age distribution for the different sites 
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The location and stage distribution of the different index tumours is given in Table 1 .  
Half of the patients had laryngeal cancer : 26 glottic carcinomas, 1 8  supraglottic 
carcinomas, 18 transglottic carcinomas and two subglottic carcinomas. 
Site and T and N 
When looking at the tumour size, it appears that sec of the hypopharynx is 
diagnosed significantly more often in an advanced stage (T3-T4) than in other 
subsites (P<0.001 Mann-Whitney U-test) . We also found a statistically significant 
difference in tumour size between tumours of the oropharyngeal region and tumours 
of the larynx, tumours of the oropharynx being diagnosed more often in an advanced 
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Table 1 : The site and stage distribution of the index primaries of 1 27 patients. 
Index primary site No Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 
oral cavity 1 4  4 4 6 
oropharynx 3 5  2 7 5 1 2  9 
hypopharynx 1 1  1 1 4 2 3 
larynx 6 4  7 1 7  1 5  2 5  
oesophagus 3 3 
Total 1 2 7  3 1 5  3 0  3 3  4 6  
No : number of patients 
stage of disease (T3-T4) than laryngeal cancer (P=0.004 Mann-Whitney U-test). 
When looking at the clinical stage of the neck (N), we found a highly significant 
statistical difference between the stage of the neck in laryngeal carcinoma compared 
with the neck stage in the other sites (p=0.007 Mann-Whitney U-test). The majority 
of the laryngeal carcinomas had no pathological lymph nodes. We found a positive 
association between the size of the tumour (T) and the clinical stage of node 
involvement (N) (rS = 0.204, p = 0.025 Spearman correlation coefficient). The larger 
the tumour, the more advanced the stage of the neck. 
3 .  Tobacco and alcohol 
The distribution of the smoking habits of the patients is shown in figure 2. Smoking 
of cigarettes is by far the most common way to use tobacco (86%) and more than half 
of the male population use non-filter cigarettes. Other tobacco habits like sniffing or 
chewing tobacco are uncommon in Belgium. 
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The distribution of the pack-years shows that the majority of the head and neck cancer 
population, men as well as women, are heavy abusers of nicotine (Fig 3). The 
distribution of alcohol intake for the whole population is shown in Figure 4. About 
half of the patients drink more than 5 units of alcohol per day. There is no proven 
statistical difference in the smoking habits for the different sites (p=0 .43 Chi-square). 
There is, however, a strong statistical significant difference between the different sites 
according to their alcohol use (p = 0.0052 Chi-square). The highest alcohol abuse was 
found in the group of oral  cavity and oropharyngeal cancer comparrd with the group 
of patients with laryngeal and hypopharyngeal cancer. We could not demonstrate a 
linear relation between tobacco and alcohol use. Heavy smokers are not necessarily 
heavy abusers of alcohol (p=0.25 Chi-square). 
Fig. 3 : Distribution of pack years of 
127 head an neck cancer patients 
Fig. 4 : Distribution of alcohol instake 

































The ORs for the sites of head and neck related to the use of tobacco and adjusted for 
alcohol are presented in Table 2. The highest ORs were seen in the oral cavity and the 
oropharynx (1 .99 and 1 .76 for heavy smokers in comparison to moderate smokers). 
The lowest ORs were seen in SCC of the hypopharynx. 
The ORs for the different sites related to the use of alcohol and adjusted for nicotine 
are given in Table 3. SCC of the oropharynx is significantly more associated with the 
use of alcohol than laryngeal cancer. A high OR was also seen in oral cavity cancer. 
Table 2 : Dose-specific odds ratios (ORs) for the use of tobacco, adjusted for the 
use of alcohol, of squamous cell carcinoma of the head and neck related to the 
different sites, using laryngeal cancer patients as a reference group . 
Sites OR 9 5 %  C I  p 
Oral cavity 1 . 9 9  0 .  3 1 < 1 . 9 9<1 5 .  9 7  0 . 6 8 
Oropharynx 1 .  7 6  0 . 45<1 .  7 6< 7 . 43 0 . 54 
Larynx 1 
Hypopharynx 0 . 5 1  0 . 1 0<0 . 5 1< 2 . 55 0 . 57 
CI : confidence interval 
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Table 3 : Dose specific odds ratios (ORs) for the use of alcohol, adjusted for the use 
of tobacco, of squamous cell carcinoma of the head and neck related to the different 
sites, using laryngeal cancer patients as a reference group. 
Sites OR 9 5 %  CI p 
Oropharynx 5 . 64 1 . 6 6<5 . 64<2 0 . 06 0 . 0 0 4  
Hypopharynx 2 . 8  
Oral cavity 2 .  71 0 . 55<2 . 7 1<13 . 93 0 . 3 0 
Larynx 1 
CI : confidence interval 
4. Delay in diagnosis of squamous cell carcinoma of the upper respiratory tract 
The referral pattern of our population under study is given in Table 4. Almost two­
thirds of our study population was referred to the university by ENT surgeons 
working in private practices. Very few patients consulted directly without any 
referral. Patients' delay was defined as the period of time between the point of 
noticing a discomfort and the time of biopsy-proven diagnosis. The delay has been 
related to patient variables such as gender, tumour stage and tumour site. The delay 
for both sexes is given in Table 5. In about half of the male patients and three-quarters 
of the female patients the diagnosis is made within three months of the beginning of 
the complaints. 
Table 4 : Referral pattern Table 5 : Delay in diagnosis of 1 26 patients 
of 127 head and neck cancer patients. with head and neck cancer related to 
gender. 
ENT- surgeon 6 9  
Generalpractitioner 3 9  Delay males ( % )  females 
noreferral 7 no complaints 6 ( 5 . 2 % )  0 
Maxillo-facialsurgeon 5 0-3 months 6 2  ( 5 3 . 4 % )  8 
Internalmedicine 4 4-6 months 2 1  ( 1 8 . 1 % )  1 
Neuro-surgeon 2 7-12 months 9 ( 7 . 7 % )  0 
Dermatologist 1 > 12 months 18 ( 1 5 . 5 % )  2 
Total 1 2 7  Total 1 1 6  1 1  
Delay - Tumour stage. 
There is no significant correlation between the tumour stage and the overall delay (rS 
= 0.090, p = 0.33 Spearman correlation coefficient) . 
Delay - Tumour site 
There is a statistically significant difference between the different sites for the overall 
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delay (p = 0.013 Kruskal-Wallis 1 -Way ANOVA). The delay in diagnosis of the 
patients with a tumour in the oropharyngeal region is shorter than the delay in 
laryngeal cancer patients (p = 0.0017 Mann-Whitney U-test). 
DISCUSSION 
More than half of the patients consulted our institution with an advanced stage of 
disease (stage ill or IV). Treatment of head and neck cancer in Belgium is not 
restricted to specialized centres. Small cancers are often treated in a private ENT 
practice. This biases the cancer population we see at the university hospital.  
As expected, we found a positive association between the size of the tumour and the 
clinical stage of the neck. There was, however, a statistical significant difference 
between the stage of the neck in laryngeal cancer and the neck stage in the other sites. 
The majority of the laryngeal cancer patients had no pathological lymph nodes. A 
possible explanation is that firstly, laryngeal cancer, in comparison with 
oropharyngeal and hypopharyngeal cancer, was more often diagnosed in an earlier 
tumour stage (T). Secondly, for glottic and subglottic carcinoma, lymphogenic spread 
occurs rather late in the course of the disease. 
The tumour size of a hypopharyngeal carcinoma at diagnosis was significantly larger 
compared to the other sites. This is probably due to two factors: the early symptoms 
of hypopharyngeal carcinoma are often aspecific; so the pre-clinical phase is long. 
S econdly, the clinical examination of the hypopharynx is difficult. 
Tobacco and alcohol are considered the most important aetiological factors in the 
development of squamous cell carcinoma (SCC) of the head and neck region 
(2,3,4,5 ,6,7,8). Other factors such as occupational or environmental factors, genetic 
or nutritional elements do not have the same importance (9,10). As both, tobacco and 
alcohol, are important aetiologic factors in the development of head and neck cancer, 
it is necessary when analysing one of the factors to control for the other. This present 
study suggests, that the RR for users of tobacco and alcohol to develop SCC of the 
head and neck, varies by anatomical site. The estimated OR of 1 .99 for heavy 
smokers with sec of the oral cavity (relative to sec of the larynx and compared with 
moderate smokers) means that for heavy smokers the RR for the development of SCC 
of the oral cavity is about twice as high as the RR for SCC of the larynx, which is 
about twice as high again (1 : 0.51 ) as the RR for SCC of the hypopharynx. For 
alcohol, however, we see that for heavy drinkers the RR for the development of SCC 
of the oropharynx is about 5 .6 times higher than the RR for SCC of the larynx, which 
is highly statistically significant. These results support the hypothesis that tobacco 
s moking is more strongly associated with lesions on sites heavily exposed to inhaled 
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smoke, whereas alcohol consumption has a stronger effect on structures belonging to 
the «food channel» and reservoir systems ( 1 1 ,12,13). Many studies have shown that 
there is a strong dose-risk relationship for nicotine as well as for alcohol and cancer 
of the upper aerodigestive tract (14).  Until now, studies examining the joint effect of 
alcohol and tobacco cannot conclude if the interaction is better described by an 
additive or multiplicative model. 
Concerning the delay, we do not know from this study if the overall delay consist 
primarily of patients' delay ( = the time period between the start of the complaints and 
the first visit to a doctor) or of doctors' delay (= the time period from the first 
consultation until the final diagnosis). The absence of a significant association 
between the overall delay in diagnosis and tumour stage is in agreement with the 
finding in the literature (15 ,16,17,18 ,1 9 ,20) . Only Mashberg et al. found that patients 
with T l  cancers had a shorter overall delay than patients with larger lesions (21) .  The 
lack of association between delay and tumour stage at diagnosis suggests that the 
tumour stage at diagnosis is determined by the intrinsic difference in tumour 
aggressiveness (17). A statistically significant correlation was found between the 
delay and the tumour site. The overall delay in diagnosis of laryngeal cancer is longer 
than oropharyngeal tumours. This reflects the specific anatomical differences between 
the different sites.  A tumour developing in the larynx gives rise very early to minor 
symptoms like hoarseness. But, in contrast to what we generally believed, dysphonia 
is apparently not considered an alarm symptom. Oropharyngeal tumours, when 
becoming clinical, give rise to serious complaints such as dysphagia, odynophagia 
and otalgia urging the patient to seek medical attention. This finding was confirmed 
by others (19,22). We can conclude that the tumour stage at diagnosis is determined 
mostly by the biology of the tumour and not so much by the delay in diagnosis. The 
delay reflects the clinical phase of the tumour which varies from site to site rather than 
it reflects the behaviour of the patient. 
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ABSTRACT 
Head and neck cancer is often associated with second primary neoplasms . These 
cancers most common1y involve other regions of the head and neck, esophagus, and 
lung. The majority of cases are also squamous cell carcinomas. In view of this rather 
frequent occurrence of multiple primary cancers and how they adversely affect the 
patient's survival, it becomes imperative to analyze how the clinician can intervene 
effectively. One such approach is to detect multiple primaries as early as possible. 
As such, panendoscopy as a part of the tumour-staging procedure has been advocated 
by many investigators to search for simultaneous second primary malignant 
neoplasms in patients presenting with head and neck cancer. In a 24-month period, 
data were gathered from 127 consecutive patients referred to University Hospital , 
Ghent with previously untreated, squamous cell carcinomas of the head and neck. 
One hundred-eighteen patients underwent an endoscopic examination under general 
anesthesia, during which 4 simultaneous second primary tumours were found in 3 
patients. This represents an incidence of 3 .4% of simultaneous second primary 
neoplasms . The results for the different parts of the endoscopy are discussed and 
compared with literature findings. Guidelines are given for the initial evaluation of 
the head and neck cancer patient. 
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INTRODUCTION 
Head and neck cancer is often associated with second primary neoplasms. These 
cancers most commonly involve other regions of the head and neck, esophagus, and 
lung. The majority of cases are also squamous cell carcinomas. When these tumours 
occur at the same time, they are called simultaneous primary tumours . 
Most early reports on multiple primary cancers of head and neck were retrospective 
studies reporting incidences varying from 3% to 30%, with an average of 5%.  Later, 
prospective studies were started that performed routine panendoscopic examinations 
of the upper aerodigestive tract. Incidences of simultaneous primary cancer were 
reported to vary from 10% to 1 6% (4,15,3 1 ,43). However, geographic and racial 
differences were found in the occurrence of simultaneous primary tumours . In The 
Netherlands, for instance, incidences of 1 .5% were reported (19) . As a consequence, 
there still is some controversy about the need to perform a panendoscopic procedure 
in every patient with an index tumour in the head and neck area. In the present study, 
we performed a prospective panendoscopic evaluation of patients presenting with a 
new, untreated cancer of the head and neck. The goals of our study were to determine 
the regional incidence of simultaneous primary tumours of the head and neck in this 
population; determine the value of bronchoscopy and bronchial washings in the 
presence of normal chest radiographs; determine the value of rigid esophagoscopy for 
detection of simultaneous esophageal cancer and to investigate the potential 
morbidity of the panendoscopic procedure. 
PATIENTS AND METHODS 
From October 1990 to October 1 992, we collected data from 127 consecutive patients 
referred to the Department of Otorhinolaryngology, University Hospital, Ghent 
(Belgium). All had previously untreated, squamous cell carcinomas of the head and 
neck. Patients with a malignancy of the skin, paranasal sinuses, nasopharynx, salivary 
glands or thyroid were excluded. 
Preoperatively, a thorough clinical examination was done that included indirect 
laryngoscopy and chest roentgenography. CT scans from the skull base to the 
clavicles were obtained in every patient. Routine contrast studies of the 
gastrointestinal system were not performed unless symptoms of dysphagia were 
indicated by history. The patients underwent a panendoscopic examination under 
general anesthesia as part of the initial staging procedure of their presenting tumour. 
After induction, patients were ventilated using high-frequency jet ventilation. 
Bronchoscopy with a rigid bronchoscope and rigid endoscopes (0° , 30°, 90° and 
1 20°) was performed first. Selective bronchial washings for cytological evaluation 
were obtained regardless of the endobronchial findings. Then rigid esophagoscopy 
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with oo and 30° endoscopes was performed. A Jako or Dedo type wide-lumen 
laryngoscope was used to view the larynx, pyriform sinuses and hypopharynx. The 
examination was concluded with final inspection and palpation of the oral cavity and 
oropharynx . Nasopharyngoscopy was performed with a Wolf Lumina 
nasopharyngoscope. 
Warren and Gates' (42) criteria were used to define a second primary tumour. The 
original presenting tumour was termed the index tumour. The site and subsites of the 
head and neck were defined according to the criteria of the International Union 
Against Cancer (UICC) and the International Classification of Diseases for Oncology 
(ICD-0). If a tumour involved more than one (sub)site, we chose the (sub)site in 
which the bulk of the tumour was localized. 
Regarding tumour size and lymph node involvement, all tumours were coded 
according to the latest UICC TNM classification (18) .  Lymph node involvement was 
determined by clinical examination together with the results of cr. Fine-needle 
aspiration biopsy was done routinely to confirm metastatic lymph node cancer. 
Simultaneously developing carcinomas were categorized as lesions that developed at 
the same time and were diagnosed at the initial presentation. These are considered to 
be a subclass of synchronous primary malignant tumours that aree defined as separate 
cancers which were diagnosed within 6 months of one another. 
RESULTS 
1 .  Age and gender distribution 
The group of 127 patients with squamous cell carcinoma of the head and neck region 
consisted of 1 1 6  men and 1 1  women (male to female ratio : 10 to 1 ) .  The mean ages 
Fig. l Distribution of 127 patients with cancer of the upper aerodigestive tract by 
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for the men and women were, respectively, 59 and 58 years . The sex and age 
distribution is shown in Fig. 1 .  
In about half of the male patients and three-fourths of the female patients the 
diagnosis was made within 3 months after the onset of complaints. 
2. Site and stage distribution 
The site and stage distribution of the different index tumours is given in Table 1 .  
Table 1 The site and stage distribution of the index primaries of 127 patients 
managed at University Hospital, Ghent 
Index primary site No Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 
Oral cavity 1 4  4 4 6 
Oropharynx 3 5  2 7 5 1 2  9 
Hypopharynx 1 1  1 1 4 2 3 
Larynx 6 4  7 1 7  1 5  2 5  
Esophagus 3 3 
Total 1 2 7  3 1 5  3 0  3 3  4 6  
Sixty-four patients had laryngeal cancer : 26 glottic carcinomas, 1 8  supraglottic 
carcinomas , 1 8  transglottic carcinomas and 2 subglottic carcinomas. There was no 
statistically significant difference between the stage distribution of the different 
tumour sites. Fig 2 shows the distribution of the patients with head and neck 
carcinoma by tumour stage and lymph node involvement. 
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3 .  Findings of the panendoscopic procedure 
A full endoscopic procedure was performed in 91 of the 127 patients . In 27 of the 
patients bronchoscopy and bronchial washings were not done because of severely 
impaired respiratory function. In 9 patients, only an examination of the oral cavity 
and oropharynx was done because of anatomical deformities or large tumours 
prohibiting endoscopy. 
Four of the 9 1  patients who underwent the full endoscopic procedure had a 
complication (45%). One loose tooth occured in one patient. In 2 patients a 
tracheotomy had to be performed during the examination because in both cases 
tumour was so bulky that detubation was considered unsafe for maintenance of an 
airway. One patient remained intubated for 2 days after the procedure because of the 
same reason. There were no deaths or major complications (such as perforation of the 
esophagus) in the patients studied. 
In the group of 1 1 8 patients undergoing endoscopy, 4 simultaneous second primary 
tumours were found in 3 male patients at the time of endoscopy (Table 2). In all, this 
represented an incidence of 3 .4% of simultaneous second primary tumours. 
Table 2 Patients with simultaneous primary tumours 
Locationls T-clasa of 11 IDeation T- class of Loc tionlrd T- 1 f Jrd Part of endoscoJ Age primary primary 2nd primar 2nd primar ,: __ • t ,c_:!� � leediDgtc Survival (month tumor tumour tumour tumour pr........._.z umour pr�..r umour dJ.egncais 
64 esophagus T4NOMO 
57 nropharynx T 4 N 3M 0 larynx 
T2 
T2 
4 2  nropharynx TJNOMO hypopharynx T2 







1 0  
Ninety-one patients underwent rigid bronchoscopy and had bronchial washings 
collected during bronchoscopy. Bilateral positive bronchial washings with a normal 
chest radiograph were considered to represent contamination. Only unilateral positive 
bronchial washings were considered to be significant and CT of the chest was 
performed. In one patient a lung tumour was found. This patient had a bronchial 
washing positive for a malignant neoplasm, but no evidence of tumour was found on 
chest roentgenograms or bronchoscopy. The diagnosis was confirmed by CT of the 
chest and flexible bronchoscopy with broncho- alveolar lavage. As the histology of 
the lung tumour (oat cell) was different from that of the head and neck tumour (which 
was a squamous cell carcinoma) there was no difficulty in fulfilling the criteria of 
Warren and Gates. The site of the primary lesion in this patient was a large cervical 
esophageal carcinoma. There were no cases in which radiography was positive and 
bronchoscopy was negative. 
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Esophagoscopy 
One hundred-eighteen esophagoscopies were performed. No second primary in the 
esophagus was found. 
Direct pharyngoscopy and laryngoscopy 
One hundred-eighteen patients underwent oro- hypopharyngoscopy and 
laryngoscopy. Two second simultaneous primary tumours were found and a third 
simultaneous primary tumour. Two tumours were supraglottic laryngeal carcinomas 
and one was a hypopharyngeal (pyriform sinus) carcinoma. The primary carcinomas 
in both patients were large (T3-T4) tonsillar carcinomas that made difficult thorough 
initial examination of the hypopharynx and larynx and prevented their diagnosis prior 
to endoscopy. All three second primary lesions were T2 lesions. 
DISCUSSION 
The reported incidence of 3.4% of simultaneous primary tumours in the aerodigestive 
tract is consistent with findings reported from the Netherlands (19) but is low 
compared to other series deriving mostly from studies in the United States (Table 3). 
The reasons for this discrepancy are multiple. In a number of American studies, a 
hospital or regional tumour registry is used for the collection of the data, which 
explains the large proportion of second tumours found outside the aerodigestive 
system. In our study, however, the prevalence data are the result of an intensive 
clinical surveillance of ENT doctors and are therefore mainly restricted to the bead 
and neck area. Secondly, racial, environmental and occupational factors are of 
importance in the development of bead and neck carcinoma. Other studies stress the 
importance of vitamin A and E as protective factors against the development of bead 
and neck cancer in general and in second primary tumours in particular (11). Thus 
nutritional habits of a population are important. The prevalence of multiple primary 
tumours also depends on the site of the index tumour. Since a lot of these parameters 
are not mentioned in the different studies, it is difficult to compare different studies 
with each other. 
Chest radiography versus bronchoscopy 
There is no clinical consensus regarding the use of either rigid or flexible 
bronchoscopy to evaluate patients with primary squamous cell carcinomas of the 
upper aerodigestive tract for the possibility of second primary cancers. Whereas its 
effectiveness in patients with questionable lesions or masses on chest radiographs is 
certain, the value of this procedure in a patient with a normal chest radiograph 
remains questionable. 
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Table 3 Incidence of simultaneous second primary carcinomas of the esophagus, 
lung and head and neck region in patients with a primary head and neck carcinoma 
(pr prospective, re retrospective) 
No 
Authors tumour No No lung 
( reference) n head % esophag % tumour % and tumour 
neck 
McGuirt ( 3 2 )  pr 1 0 0  6 6 %  8 8 %  3 3 . 0 % 
Maisel ( 3 1 ) pr 4 4 9  1 2  2 .  7 %  4 0 . 9 % 1 7  3 . 8 % 
Weaver ( 4 3 )  pr 1 2 4  1 1  8 . 9 %  3 2 . 4 %  2 1 .  6 %  
Atkins ( 3 )  pr 4 5 1  5 1 . 1 % 3 o .  7 %  3 0 .  7 %  
Leipzig(29 ) pr 3 8 4 1 4  3 . 6 % 7 1 . 8 %  1 3  3 . 3 %  
Parker (33 ) pr 2 0 8  1 0  4 . 8 %  4 1 . 9 %  3 1 .  4 %  
Lau ( 2 7 )  pr 1 0 5  5 4 . 8 %  6 5 . 7 %  1 1 .  0 %  
Gluckman ( 15)  pr 1 6 2 1 2  7 . 4 %  2 1 . 2 %  1 0 . 6 % 
Grossman ( 1 6 )  re 6 9 6  2 5  3 . 6 %  6 0 . 9 % 7 1 .  0 %  
Schuller ( 3 5 )  pr 5 3  3 5 .  7 %  0 0 %  2 3 .  7 %  
Hordijk ( 1 9 )  pr 1 0 0  1 1 %  0 0 %  1 1 % 
Atkinson ( 4 )  pr 2 7 1  1 3  4 . 5 %  1 2  4 . 4 %  3 1 . 1 % 
Choy ( 8 )  pr 5 7 3  1 0 . 2 %  8 1 .  4 %  1 0 . 2 %  
Present series pr 1 1 8 3 2 . 4 %  0 0 %  1 0 . 8 %  
Shapsay ( 36 ) pr 1 5 0  9 6 %  
Abemayor ( 1 )  pr 1 5 0  3 2 %  
Grossman ( 16 ) pr 2 5 4  4 1 . 6 %  
n :  number of patients with Head and Neck cancer 
No : number of patients with simultaneous primary cancer 
The incidence of a second synchronous primary cancer in the lung varies from 0.2% 
to 3 .8% (Table 3). Table 4 gives the yield of bronchoscopy in detecting simultaneous 
primary lung tumours in patients with a normal chest radiograph. The chest 
roentgenogram is not an absolute indicator of the presence of second primary lesions 
in the lung. But because of the very low yield, an argument can be made against 
including rigid bronchoscopy as part of the panendoscopic evaluation when the chest 
roentgenogram is normal. 
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Table 4 Yield of bronchoscopy in detecting simultaneous primary lung tumours in 
patients with normal chest radiographs (n number of patients with head and neck 
cancer) 
Author n No No ' No ' /No 
(Reference ) 
Leipzig ( 28 )  9 8  3 %  3 %  1 0 0 %  
Vrabec ( 4 1 )  1 5 1 8  0 . 6 % 0 . 3 %  5 0 %  
McGuirt ( 3 2 ) 1 0 0  3 %  1 %  3 3 %  
Maisel ( 3 1 )  4 4 9  3 . 8 % 0 %  0 %  
Parker ( 3 3 ) 2 0 8  1 .  4 %  0 . 5 % 3 6 %  
Present series 1 2 7  0 . 8 % 0 . 8 % 1 0 0 %  
No : number of patients with simultaneous primary lung carcinoma 
No' : number of patients with simultaneous primary lung carcinoma detected only 
by either rigid or flexible bronchoscopy 
No '/No : percentage of the total number of patients with simultaneous primary lung 
carcinomas detected only by bronchoscopy 
In general, the sensitivity of rigid bronchoscopy is rather low (10;27). Examination 
using a fiberoptic endoscope is increasing in popularity. The flexible instrument is not 
as traumatic as the rigid instrument because of its flexible shaft and its smaller caliber. 
Examination of the lungs can be performed more thoroughly and segmental bronchial 
washings can readily be obtained (9,14,21 ,354). Conventional white light 
bronchoscopy , however, fails to detect precancerous or early lung lesions in about 
10-20% of cases. A report by Woolner and colleagues (44) showed that even for 
centrally located squamous cell carcinomas, carcinoma in situ was visible to the 
experienced bronchoscopist in only 29% of cases . 
Fluorescence bronchoscopy has been developed over the last two decades to address 
the limitations of conventional techniques ( 5 ,  17). This type of bronchoscopy uses 
fluorescing drugs that are preferentially retained in tumours. However, their 
diagnostic effectiveness has been limited because these tumour-localizing drugs ,  such 
as Photofrin or Hematoporphyrin Derivative, have serious side effects of prolonged 
skin photosensitivity (12).  Lam et al. (23;24) showed in experimental and clinical 
studies that carcinoma in situ could be detected with much lower dose of Photofrin II 
with no apparent skin phototoxicity. An exciting finding was their discovery that 
detection of dysplasia and carcinoma in situ could be achieved without using any 
drug at all (20;21 ;22;25). Using a helium-cadmium laser (442 nm) for illumination, 
they saw a significant decrease in autofluorescence intensity in areas with dysplasia 
or carcinoma in situ compared to normal bronchial tissue. Using this technique, they 
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were able to increase the sensitivity of the fluorescence system to 72.5% in detecting 
dysplasia and carcinoma in situ, which is 50% higher than that of the white light 
bronchoscopy (22,25). Although not available at all medical centers, this technique is 
an important adjunct to conventional white light examination for improving the 
ability to diagnose lung cancer even in a very early stage. 
In our opinion, rigid bronchoscopy should not be performed routinely at the initial 
work-up of the head and neck cancer patient if a chest radiograph is normal. Flexible 
bronchoscopy with segmental bronchial washings and in some occasions using 
fluorescence imaging may have a higher yield, but more data are necessary before 
definite conclusions can be drawn. As most lung tumours occur metachronously in 
head and neck cancer patients, the biggest advantage will lay in the course of follow­
up. 
The role of esophagoscopy in the initial work-up 
The incidence of simultaneous primary esophageal tumours is relatively low in a 
Western population. In our study, no simultaneous primary tumours of the esophagus 
were detected. Most authors report an incidence of 1-2%, although some studies have 
found incidences as high as 6-8% (Table 3). Studies reporting the results in a Chinese 
or Japanese population note a definite higher incidence of second primary esophageal 
cancer (26). Considering the overall number of simultaneous asymptomatic 
esophageal malignancies, incidences are still lower (Table 5). This explains the 
divergence of opinion among otolaryngologists on the value of esophagoscopy as a 
routine screening procedure at the initial evaluation of a head and neck cancer patient. 
Further, survival after diagnosis of any primary esophageal cancer has been poor 
Table 5 Incidence of simultaneous oesophageal malignancies 
Author n No No ' No ' /No 
McGuirt ( 3 2 ) 1 0 0  8 % 3 .  7 %  4 6 %  
Atkinson ( 4 )  2 7 1  4 . 4 % 1 . 1 % 2 5 %  
Shapsay ( 3 6 )  1 5 0  6 %  2 .  7 %  4 5 %  
Choy ( 8 )  5 7 3  1 .  4 %  0 . 9 % 6 4 %  
Atabek ( 2 )  5 7 4  1 %  0 . 2 % 2 0 %  
Present series 1 2 7  0 %  0 %  
n : number of patients with head and neck cancer 
No : percentage of simultaneous esophageal malignancies 
No ' : % of simultaneous asymptomatic esophageal malignancies, No' /No 
percentage asymptomatic esophageal malignancies of the total number of 
esophageal malignancies 
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(30,32). This is due to the presentation of most patients with an advanced stage of 
disease (29). At time of diagnosis , only 30 % of patients on average, are actually 
considered resectable and curable (7 ,38). Five-year survival rates after combination 
surgery and radiation therapy are generally in the range of 15-25% (13). Even worse, 
in a study of 153 cases of primary esophageal cancer patients reported by Takita et al 
(39), there was only a 2% 5-year survival rate with surgery and radiation therapy. The 
same poor survival was found in a prospective study reported by Shapsay's group (36). 
The value of screening lies in the ability to find esophageal cancers at an early, 
curable stage. However, to date there is no convincing evidence that esophageal 
screening during initial workup of head and neck cancer patients leads to diagnosing 
smaller tumours and better survival rates . 
A last element to be considered when evaluating the value of rigid esophagoscopy is 
its complication rate. In our series we had no complications, but ours was a small 
series of patients . In the literature, the incidence of instrumental perforation varies 
from 0.2-0.8%, depending on the type of endoscopic procedure used (6,37 ,40,45).  
The risk of perforation with rigid or open-tube endoscopy is much greater than with 
flexible endoscopy. Although the incidence is low, the mortality can be as high as 
16% (6). 
From the various data reviewed, we cannot recommend esophagoscopy as a 
screening procedure in every head and neck cancer patient. On the other hand, 
esophagoscopy should be performed at the initial evaluation of the head and neck 
cancer patient with complaints of dysphagia or with symptoms not specific enough to 
be attributed to a head and neck tumour. Esophagoscopy is also warranted in patients 
with tumours that can possibly invade the esophagus as a consequence of their 
localisation or volume. 
Value of direct laryngoscopy. 
A large proportion of the simultaneous second primary cancers are located in the head 
and neck region, especially with an index tumour in the oral cavity, oropharynx or 
hypopharynx (Table 3). In our series, two of the three simultaneous second primaries 
were located in the oro-hypopharynx and larynx. Both were not diagnosed prior to 
endoscopic investigation. The reason is that it is often difficult to thoroughly examine 
the mucosa of the hypopharynx and especially that of the pyriform sinuses, the 
retrocricoid area, vallecula and posterior pharynx by indirect laryngoscopy, especially 
in the presence of another head and neck tumour. 
Despite the low yield of second tumours, we support the use of oro-hypopharyngo­
laryngoscopy as a screening procedure. All patients who present with head and neck 
cancer should undergo such endoscopy, not only for evaluation of the index tumour 
but also for evaluation of the entire mucosa of the oral cavity, oropharynx, 
hypopharynx and larynx. 
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ABSTRACT 
The results of 127 rigid bronchoscopies with bronchial washings in patients with a 
new, untreated head and neck tumour and a normal chest radiograph were analysed 
for their usefulness in detecting simultaneous primary lung carcinomas. All patients 
were followed for a minimum of 2 years or till death. 
We found positive bronchial washings in 19 cases (21 %). Unilateral positive 
bronchial washings were found in 8 patients (9%). In only one patient a simultaneous 
primary lung tumour was found. One patient was found to have a pulmonary 
metastasis. The remaining 6 patients with positive unilateral cytology (6/8) had 
normal chest roentgenograms and/or CT scans and did not develop a lung tumour in 
the course of follow-up. Of the 19 positive bronchial washings, 10 patients had a 
carcinoma of the larynx and two had a large hypopharyngeal carcinoma. 
Contamination of bronchial washings with tumours cells from head and neck 
neoplasms limited seriously the usefulness of positive bronchial cytology. 
The sensitivity and specificity of the rigid bronchoscopy with bronchial washing is 
too low to justify its cost. 
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INTRODUCTION 
There is a high incidence of second primary neoplasms in patients with a known 
squamous cell carcinoma of the upper aerodigestive tract. Five to 30% of patients 
with a head and neck carcinoma will develop a second primary tumour, most 
frequently in the upper aerodigestive tract, lung and oesophagus.  A small percentage 
of these second primary tumours are detected simultaneously, at the diagnosis of the 
initial head and neck tumour. From several reports we know that the incidence of 
simultaneous second primary carcinomas of the lung varies from 0.5 to 3 .8%, and that 
the association is especially frequent with oral and laryngeal carcinoma (1).  
Therefore, during the initial work-up of a patient with head and neck cancer, many 
authors suggest screening with a rigid bronchoscopy with bronchial washings to 
detect a possible simultaneous second primary lung tumour. 
When reviewing the literature concerning the usefulness of rigid bronchoscopy with 
cytodiagnosis of bronchial washing to detect bronchogenic carcinoma, there is a great 
deal of controversy. Some authors have reservations concerning the usefulness of the 
technique in the presence of a known primary tumour in the upper aerodigestive tract 
because of shedding of malignant cells of the primary head and neck tumour in the 
tracheobronchial tree (2). Others report only sporadic shedding of malignant cells 
into the tracheobronchial tree despite the use of rigid bronchoscopy (3 ,4) . 
In North America, the flexible bronchoscope is used by most otolaryngologists in 
contrast with most European centres, however otolaryngologists are trained in the use 
of the rigid bronchoscope, the flexible bronchoscope being almost exclusively the 
tool of the lung specialists. Therefore, the objective of the present study was to look 
at the value of rigid bronchoscopy and cytodiagnosis of bronchial washings in the 
early detection of bronchial carcinoma in patients treated for a primary squamous cell 
carcinoma of the upper aerodigestive tract. 
METHODS AND MATERIAL 
From October 1990 to October 1992, we collected data of 127 consecutive patients, 
referred to the Department of Otorhinolaryngology of the University Hospital of 
Ghent (Belgium) with a previously untreated, squamous cell carcinoma of the head 
and neck region. Patients with a malignancy of the skin, the paranasal sinuses, 
nasopharynx, salivary glands or thyroid were excluded. Patients with a pulmonary 
malignancy diagnosed by a radiologist on a chest radiograph, were also excluded 
from this series. 
Preoperatively, a thorough clinical examination with indirect laryngoscopy and a 
chest roentgenography was done. CT scans from skull base to clavicles were taken in 
every patient. Each patient, regardless of the site and stage of his index tumour, 
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underwent a panendoscopic examination under general anaesthesia as part of the 
initial staging procedure of their presenting tumour. After induction, patients were 
ventilated using an endotracheal tube of 4 rnm diameter and high frequency jet 
ventilation. Bronchoscopy with the use of the rigid bronchoscope and rigid 
endoscopes (0° ,30° ,90° ,120°) was performed first. A rigid Jackson bronchoscope was 
used in all cases. The bronchoscope was passed through the larynx adjacent to the 
endotracheal tube. No attempt was made to wash the instrument after passing through 
the upper airway prior to obtain bronchial washings. Each main-stem bronchus was 
then irrigated with 1 Occ normal saline and aspirated for cytology in separate 
containers. The specimens were labelled and sent for cytologic evaluation. Smears 
were made: half of them were fixed in 96% ethanol and the other half were air dried. 
The fixed smears were stained by the Shorr technique. The air-dried smears were 
stained bij the modified May-Grunwald stain. The cytologic findings were reported in 
descriptive terms as ( 1 )  cell smears without evidence of inflammatory or 
preneoplastic or neoplastic changes; (2) smears without preneoplastic or neoplastic 
changes but with increase of inflammatory cells; (3) smears containing cells with 
some nuclear features of malignancy but not enough to be concluded as possible 
malignant and ( 4) smears with obvious atypical cells diagnosed as suggestive of 
malignancy. The tentative diagnosis is also suggested. 
At the end of the study, all specimens were reviewed by the same cytologist. Only 
specimens diagnosed as class 4 were considered positive. Warren and Gates' criteria, 
modified by Hong, were used to define a second primary tumour (5 ,12) .  All patients 
were followed for a minimum of 2 years or till death occurred, in order to determine 
whether a bronchogenic carcinoma had been present which was not detected by the 
bronchial washing. 
RESULTS 
We performed a full endoscopic procedure in 91 of the 127 patients. In 36 of these 
patients, bronchoscopy and bronchial washings were not done because of severely 
impaired respiratory function, or were not possible technically because of large 
tumours in the upper aerodigestive tract prohibiting endoscopy. 
The bronchial washings were positive in 1 9  cases (21 %). However, bilateral positive 
bronchial washings with a normal chest X-ray film were considered as contamination, 
and no further investigations were done. In 8 cases (9%), we found an unilateral 
positive bronchial washing (fable 1) .  In those patients, the radiograph of the chest 
was reevaluated, and if necessary, a CT scan of the chest was performed. A lung 
tumour was found in one patient. This patient had a bronchial washing that was 
positive for a malignant neoplasm, but no evidence of tumour on chest 
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roentgenograms or bronchoscopy. The diagnosis was confirmed by a CT scan of the 
chest. As the histology of the lung tumour (oat cell) was different from that of the 
head and neck tumour (squamous cell carcinoma) there was no difficulty in fulfilling 
the criteria of Warren and Gates. The site of the primary lesion in this patient was a 
large cervical esophagial carcinoma. One patient with a large oropharyngeal 
carcinoma presented with a pulmonary metastasis at the time of diagnosis. He had a 
positive bronchial washing and an abnormal CT scan. He committed suicide 16  days 
after diagnosis .  The remaining 6 patients with positive cytology (6/8) had normal 
chest roentgenograms and/or CT scans, four of whom were still alive at the end of the 
study without any signs of a lung carcinoma (minimum follow-up of 2 years) . Two of 
these patients died of their head and neck tumour with no further evidence of a lung 
neoplasm. 
An interesting finding was that, of the 19 positive bronchial washings ,  10 patients had 
a carcinoma of the larynx and two had a large (T3 and T4) hypopharyngeal carcinoma 
Two of the 1 1  patients with bilateral bronchial washings that had been considered as 
contamination at the time of diagnosis,  developed a lung carcinoma: one after 8 
months and the other after 15 months. 
Table 1 : Patients with a known primary tumour of the head and neck with a unilateral 
positive bronchial washing. 
Dateofbirtprimary 'll' N M  BW-R* BW- L *  RX and/ Survival 
( d/m/ y )  o r  CT chest 
30 0 7  39 1 6 1  3 . 1. 0 .  5 2 CT chest nl alive at 1 0/94> 27 month! 
0 9  03 22 1 6 1 . 0  2 . 0 . 0 .  5 2 RX chest nl alive at 1 0/94> 36 month! 
3 1  0 7  48 1 6 1 . 0  2 . 0 . 0 .  3 5 CT chest nl alive at 1 0/94> 40 month! 
10 1 0  2 5  1 4 1 . 0  4 . 0 . 1 .  5 3 CT chest abno dead( suicide) 16 days 
0 1  0 2  1 4  1 6 1  3 . 2 . 1 .  2 4 RX chest nl alive at 1 0/94> 28 month! 
29 06 27 1 5 0  4 . 0 . 0 .  5 2 CT chest abno dead 2 1 / 2  mon 
1 9  1 1  23 1 4 8  4 . 2 . 0 .  3 5 RX chest nl dead of primary1'1l months 
25 03 56 1 44 . 0  3 . 1 . 0 .  2 5 CT chest nl dead of primar}e'nnonths 
T= tumour; BW= bronchial washing; R= right; L= left; nl= normal; 
abno= abnormal; RX= chest radiograph; CT= computerized tomography. 
* Papanicolau Class 
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DISCUSSION 
There is still a lot of controversy concerning the value of bronchial cytology in the 
detection of a lung neoplasm in the presence of a known head and neck carcinoma, 
especially if the cell type is similar. When looking at different studies, the 
contradictory results are partially explained, in our opinion, by differences in 
technique and the characteristics of the population examined. 
Garfinkle et al. performed flexible bronchoscopy on 107 patients with head and neck 
cancer (2). In about half of the cases, the bronchoscope was passed through the 
endotracheal tube, whereas the bronchoscope was passed adjacent to the endotracheal 
tube in the remaining cases. Two patients were found to have a lung neoplasm. 
Thirteen patients (13%) had false-positive bronchial washings. Most of these 
patient's primary tumours were located in the larynx. An interesting finding was that 
the majority of the false-positive washings ( 10/1 3) occurred when the bronchoscope 
was passed adjacent to the endotracheal tube when compared with the technique in 
which the bronchoscope was passed through the tube. Denneny et al. performed a 
flexible bronchoscopy in 150 patients with a primary carcinoma of the head and neck 
(6). The majority of the bronchoscopies were performed through an endotracheal or 
tracheotomy tube. There was no information about the site of the index tumour. Four 
patients were found to have concomitant primary lung neoplasms; they reported no 
false-positive cytology result in their series .  Dellon et al. found no false-positive 
cytology results in a series of 1 8  patients with head and neck cancer who underwent 
flexible bronchoscopy with bronchial washings under local anaesthesia (4) . Johnson 
et al. reported only one false-positive cytologic result from a bronchial washing in a 
series of 100 patients with a head and neck cancer (3). They performed rigid 
bronchoscopies, and half of their population had a laryngeal carcinoma. 
Our results confirm the observation of Garfinkle et al. In our study, contamination of 
bronchial washings with tumours cells from head and neck neoplasms did take place 
and seriously limited the usefulness of positive bronchial cytology. The assumption 
that we made about bilateral positive bronchial washings being due to contamination 
is possibly also not valid, because 2 of the 1 1  patients did develop a lung carcinoma. 
The majority (8/13) of the patients with false-positive bronchial washings in both the 
study by Garfinkle et al. and in ours (10/17) are patients with laryngeal cancer. This 
probably explains why Dellon et al. found no false positive bronchial washings in 
their small series of 1 8  patients. Most of the head and neck tumours did not lie in 
proximity to the path of the bronchoscope (8/18 oral cavity carcinomas and only one 
laryngeal carcinoma). It is also evident that the larger the tumour, the more likely 
contarninationcan occur in the tracheobronchial tree. 
Most authors agree that shedding of malignant cells from the head and neck primary 
into the tracheobronchial tree is unusual. (2 ,3 ,4, 1 1 )  Malignant cells desquamate but 
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are cleaned by mucociliary transport that goes upwards. However, contrary to 
previous reports, contamination of the bronchial washings with malignant cells from 
the head and neck primary tumour can occur in those situations when the 
bronchoscope, rigid or flexible, is passed through the larynx adjacent to the 
endotracheal tube in close contact with the tumour. False positive cytology findings 
occur most commonly in cases of carcinoma of the larynx, so contamination of the 
bronchial washings is probably attributable to direct contact of the bronchoscope and 
the tumour. Passage of the flexible fiber-optic bronchoscope through the endotracheal 
tube avoids mechanical contact with the tumour and provides more reliable cytologic 
specimens. 
CONCLUSION 
The incidence of simultaneous primary lung carcinomas is low, therefore, we believe 
that the sensitivity and specificity of the rigid bronchoscopy with bronchial washings 
is too low to justify its use. The use of the flexible bronchoscope seems to be superior 
for examining the lung for possible malignant lesions. First of all, it can be passed 
through the endotracheal tube and, therefore, enables bronchial washings to be 
performed without traumatizing the head and neck tumour. Second, it enables 
visualization of peripheral bronchial segments up to the fourth and fifth order, and 
washings can be isolated from specific segments. Flexible instrumentation also 
allows better evaluation of the upper lobe. 
Additional techniques have been developed to augment the sensitivity of 
bronchoscopy, such as fluorescence bronchoscopy using fluorescing drugs that are 
preferentially retained in tumours (7) or the recent use of autofluorescence intensity 
in areas with dysplasia or carcinoma in situ, compared to normal bronchial tissue, 
using a helium-cadmium laser (442 nm) for illumination (8,9,10). 
As most of the lung tumours occur metachronously in the first 2 years after diagnosis 
of the primary tumour, even the use of a flexible bronchoscope as a routine screening 
procedure in head and neck cancer patients with a normal chest X-ray film is still 
open for discussion. Perhaps the greatest value of the flexible bronchoscope lies in its 
use for the follow-up of head and neck cancer patients. 
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ABSTRACT 
Multiple primary tumours are a known phenomenon in head and neck cancer. They 
are partially responsible for the limited improval in survival of head and neck cancer 
during the last 20 years. Only a few prospective data have been published about the 
incidence of metachronous tumours. We prospectively studied 127 patients with 
squamous cell carcinoma of the head and neck. The overall incidence of second 
primary tumours was 13 .5% (simultaneously = 3%, synchronously = 5 .5% and 
metachronously 8% ). More then 90% of the recurrences of the first primary tumour 
occurred within the first two years following primary treatment, but the second 
primary tumours continued to occur gradually in the course of follow-up. Most of the 
second primary tumours were discovered because the patients developed symptoms 
(14/17). Survival after detection of the second primary tumour was poor. The 
development of a second primary tumour was of equivalent prognosis than a 
recurrence of the primary tumour. Future directives are the development of more 
adequate screening methods. Identification of potential early markers for the 
development of a squamous cell carcinoma at the level of the mucosa at risk, and in 
serum could be of value for the early detection of individuals at risk. 
Chemoprevention is another promising tool in the prevention of development of 
second primary cancer. 
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INTRODUCTION 
Squamous cell carcinoma of the upper aerodigestive tract is known to be frequently 
associated with a second primary carcinoma. A series of retrospective studies have 
been published giving incidences of second primary tumours varying from 5% to 
30%. This knowledge resulted in prospective studies looking for synchronous and 
metachronous multiple primary tumours . As was expected, in prospective studies, 
incidences of synchronous tumours were even higher. However, only a few 
prospective data have been published about the incidence of metachronous tumours 
(Table 1).  
Table 1. Incidence of synchronous and metachronous multiple primary tumours in 
squamous cell cancer of the head and neck (prospective studies only) 
FirstAuthor year lcx:at:i.al n Second primary follow-up 
( reference) synch metaclu: total ( in months 
Weaver ( 1 )  7 9  Michigan 1 2 4  1 3 %  7 %  2 0 %  2 4  
Atkinson ( 2 )  8 2  Michigan 2 7 1  1 0 . 3 %  1 5 . 1 % 2 5 . 5 % 5 8  
Atkins ( 3 )  8 4  Philadelph 4 5 1  2 . 5 % 8 . 5 % 1 1 %  1 2 0  
Choy ( 4 )  9 1  Bong Kong 5 7 3  1 .  9 %  0 . 5 % 2 . 4 %  22 ( mean ) 
n : index tumour cases 
Demographic variations in patterns of head and neck malignancies imply that the 
incidence of multiple primary tumours published in literature cannot unquestionable 
be extrapolated to different countries . Therefore we conducted a prospective study of 
patients with head and neck malignancies undergoing treatment and follow-up at the 
Department of Otorhinolaryngology at the University Hospital of Ghent. 
The aims of the study were: 
1 )  To quantify and characterize the problem of multiple primary malignancies .  
2 )  To look at the implications of the appearance of a second primary tumour on 
survival. 
3) To derive guidelines for follow-up of patients with head and neck cancer. 
MATERIALS AND METHODS 
A detailed prospective analysis has been carried out of 127 consecutive, previously 
untreated patients with squamous cell carcinoma of the head and neck region referred 
to the Department of Otorhinolaryngology of the University Hospital of Ghent 
(Belgium) , between October 1 990 and October 1992. Only squamous cell carcinoma 
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of the oral cavity, the oropharynx, the hypopharynx, the larynx and the cervical 
esophagus were included. Patients with a malignancy of the skin, the paranasal 
sinuses, nasopharynx, salivary glands or thyroid were excluded. After treatment, 
follow-up visits were performed every three months . During the follow-up visits only 
a clinical examination of the upper aerodigestive tract was performed. Every year a 
standard X-ray of the chest. was taken. We did not routinely perform flexible 
esophagoscopy or bronchoscopy. We had a minimum follow-up of 24 months. In this 
analysis, we specifically looked for recurrences of the index tumour and the 
appearance of second primary tumours in the upper aerodigestive tract and the lung. 
To define a second primary tumour Warren and Gates criteria modified by Hong were 
used (5,6). These criteria require that 1 )  both tumours are histologically malignant, 2) 
they must be separated by at least 2 em of normal, healthy mucosa, 3) the possibility 
of the second tumour representing a metastasis must be excluded. 
The original presenting tumour, which brought the patient to examination, was 
termed the index tumour. During the follow-up period, all lesions which occurred at 
the same site or direct vicinity ( <2 em) of the index tumour were considered as 
recurrences. 
The tumours were also classified according to their temporal sequence as formulated 
by Moertel (7).  Synchronous tumours included those that presented either 
simultaneously or within a 6 months period of identification of the original tumour. 
Metachronous tumours were identified as tumours diagnosed more than 6 months 
after the index tumour. 
The site and subsites of the head and neck were defined according to the criteria of 
the International Union Against Cancer (UICC) and the International Classification of 
Diseases for Oncology (ICD-0) (8) . In case a tumour involved more than one 
(sub)site, we retained the (sub)site in which the bulk of the tumour was localized. 
Regarding the tumour size and lymph node involvement, all tumours were coded 
according to the latest UTCC TNM classification (8). 
At the initial diagnosis, a panendoscopic examination was performed in every patient 
to look for simultaneous primary tumours . The results of this procedure have been 
described elsewhere (9). The follow-up has been described in person-years of follow­
up. The number of years at risk of a second primary tumour was calculated until the 
date of the diagnosis of the second primary tumour, until October 1995, until the 
patient's death or the date of the last follow-up visit, whichever occurred first. 
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STATISTICAL ANALYSIS 
Survival analysis was conducted using Kaplan-Meier estimates. Cox proportional 
hazard models were fitted to estimate risks of death or tumour relapse adjusted for age 
and sex. All statistical tests were two-sided. 
RESULTS 
1 .  General 
1 27 patients with a newly diagnosed head and neck malignancy, admitted to the 
Department of Otorhinolaryngology of the University Hospital in Ghent between 
October 1990 and October 1992, were included in the study. This group consisted of 
1 16 men and 1 1  women (male to female ratio : 10 to 1) .  The median age for the men 
was 59 years and for the women 58 years . By the time of the record review (October 
1 995) ,  86 patients (68%) were still alive. We had a total of 354,5 person-years of 
follow-up. The mean follow-up time for the whole group was 30 months (1-77 
months).  
2.  Site and stage distribution of the index tumour 
The site and stage distribution of the different index primaries is given in Table 2.  
Half of the patients had laryngeal cancer; 26 glottic carcinomas, 1 8  supraglottic 
carcinomas , 1 8  transglottic carcinomas and 2 subglottic carcinomas. Smoking and 
alcohol habits of the patients are described elsewhere (10).  
Table 2. Site and stage distribution of the index primaries of 1 27 patients 
Index primary site n Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 
oralcavity 1 4  4 4 6 
oropharynx 3 5  2 7 5 1 2  9 
hypopharynx 1 1  1 1 4 2 3 
larynx 6 4  7 1 7  1 5  2 5  
oesophagus 3 3 
Total 1 2 7  3 1 5  3 0  3 3  4 6  
n : number of patients 
In terms of initial therapy, 1 17 patients were treated with a curative option and 10 
patients with a palliative intent. The treatment of the index tumour i s  given i n  Table 
3 .  Seven patients (5 .5%) were lost to follow-up. Forty patients developed a recurrence 
of their primary tumour (31%) and 17 patients developed a second primary tumour 
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(13 .5%), either simultaneously (3%), synchronously (5.5%) or metachronously (8%). 
Time to tumour relapse (= recurrence or second primary) is represented in figure 1 .  
Table 3. Initial therapy of 1 27 patients with head and neck carcinoma 
Curative 1 1  � 
Palliative 1 0 
Radiationtherapy 6 2  
Surgery/radiationtherapy 3 4  
surgery 1 4  
Chemotherapy /radiation therapy 1 3  
Chemotherapy/surgery/radiation therapy 3 
Chemotherapy 1 
Median time to first relapse was 40 months . Age and gender were not predictors of 
tumour relapse : p values derived from Cox model were of 0.3 1  for age, and 0.73 for 
gender. 
Figure 2 shows the time to recurrence of the index tumour or occurrence of second 
Fig. 1. Time to first tumor relapse 
11R01JABILITY (•e�) 
N 127 p:a1len1s 
MONTHS AFTER DIAGNOSIS OF INDFX TUMOR 
primary tumour. In our series 90% of the recurrences of the first primary tumour 
occurred within the first two years following primary treatment; thereafter we reached 
a saturation point. For the occurrence of second primary tumours, we saw a steep 
rising cumulative distribution function during the first months but they continued to 
occur gradually in the course of follow-up. 
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3 .  Symptoms leading to diagnosis 
In the majority of the patients (72%), the diagnosis of recurrence was made during 
the scheduled follow-up visits. Often the patient reported suggestive symptoms or 
signs during this visit. Also, most of the second primary tumours were discovered 
because the patients developed symptoms (14/17).  In 3/17 cases the asymptomatic 
tumour was found because of the routine radiographic examination of the lungs 
during follow-up. All patients with second primary tumours in the esophagus had 
symptoms. 
4. Incidence and location of second primary tumours 
The incidence and location of the second primaries for the four different sites are 
given in Table 4. The most frequent sites of development of a second malignant 
tumour were the lung (41 %) and the head and neck region (35%). Esophageal second 
primary tumours occurred in 24% of the cases. Of the second primary tumours, all the 
esophageal and 617 lung tumours were advanced stages of disease and treated with 
palliative intent. Five of the 6 head and neck second primary tumours were stage 1 
tumours. 
5 .  Survival 
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Overall survival is shown in Figure 3 .  75% median survival is 20 months. Patient's 
age (p=0.69) and patient's sex (0.76) did not influence the survival. 
As shown in Figure 4, 75% median survival decreased substantially to 14 months in 
Fig. 2. Survival analysis for all patients 
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case of tumour relapse. 
Table 5 displays results from Cox regression model including age, gender and tumour 
Fig. 4. Survival analysis according to relapse 
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relapse. Evidence of tumour relapse was significantly associated with shorter 
survival . Risk of death was approximately two times higher for patients with relapse 
as compared to patients without a relapse. 
The survival of the group of patients developing a recurrence of the index tumour was 
Table 5. Cox regression of survival data (N = 127 patients) .  Hazard rates are adjusted 
for all factors 
Factor Adjusted Bazar 95% Confidenco p value Rate Interval 
Relapse or second prim. 2 . 0  1 . 1-3 . 7 0 . 0 2 9  
tumour ( never I ever ) 
Sex Female 0 . 9  0 . 3-2 . 4  0 . 7 6 
Aqe ( continuousvariable ) 1 . 0  0 .  9 - 1 1  0 . 6 9 
compared with the survival of those developing a second primary tumour (Figure 5 
and Table 6). As shows fig 5 ,  data censoring was well balanced between observed 
groups, hence, biases in length of follow-up due to severity of disease is not likely to 
have been present in this data set. Although the decreased size of patients in each 
strata lowers the power of the analysis, the development of a second primary tumour 
seems of equivalent prognosis than a recurrence of the primary tumour. Of the 17 
patients who developed a second primary tumour, 7 died as a result of their second 
tumour. For those patients who died as a result of their second primary cancer the 
mean survival from diagnosis of second tumour to death was 7 months (0-16 months).  
Table 6. Cox regression of survival data (N = 127 patients) 
Factor Adjusted Hazard 95% Confidence p value Rate Interval 
Recurrence 1 . 9  1 . 0-3 . 7 0 . 5 9 
Second primary 2 . 3  0 . 9-5 . 6  0 . 07 8  tumour 
Sex Female 0 . 9  0 . 3-2 . 4  0 . 7 6 
Age ( continuous 1 . 0  o .  9-1 . 1  0 . 6 9 variable) 
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Fig. 5. Survival according to recurrence or second primary tumor 
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DISCUSSION 
The occurrence of second primary tumours and its impact on survival has received 
much attention in the last 15  years. This phenomenon is especially important in head 
and neck cancer because it has been shown that patients with head and neck cancer 
have a greater risk of a second primary malignancy than any other group of patients 
with cancer ( 1 1 ,12,13). The incidence of 1 3 .5% of second primary neoplasms is in 
accordance with the literature (Table 7) (14).  In this study as well as in most follow-
Table 7. 5-year second cancer incidence between subgroups based on the site of 
index tumour (based on Schwartz et al. 1 994 (14)) 
Index tumour mobiletongue base of tongueoralcavity tmsil.lae pyriform sinus larynx 
Incidence SPT 1 0 %  4 6 %  1 8 %  1 5 %  3 4 %  2 3 %  
up studies , we see that the majority of the recurrences of the index tumour occur 
within 2 years of initial diagnosis but there is, however, a constant and continuing risk 
of second primary tumours all over the years that follow initial treatment, varying 
from 2.7%/year to 4%/year depending on the site of the index tumour ( 15 ,16,17 ,18) .  
After 36 months the appearance of a second primary carcinoma is the most common 
cause of failure ( 18 ,19,20). After 5 years of follow-up the chance of death from a 
second cancer is more than twice the risk of death from the index tumour ( 18 ,19 ,20) . 
So the follow-up should shift away from the detection of local recurrence towards the 
detection of a second primary once the patient has survived 3 or 4 years after a 
primary head and neck carcinoma and this should be continued for long periods, if 
not lifelong. 
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Our study suggests that the impact of a second primary cancer on survival equals that 
of a recurrence of the primary tumour. Other studies confirm the bad prognosis once 
a second primary tumour has developed (18,20,21 ,22). The reasons for this poor 
outcome are multiple: the poor prognosis of esophageal and lung tumours, late 
diagnosis due either to inadequate initial evaluation or insufficient follow-up, and the 
inability to effectively treat the second tumour because of the effect of prior therapy 
for the first neoplasm. 
In this context, early detection and cbemoprevention strategies appear presently the 
best options to reduce morbidity and mortality related to multiple primary cancers. 
There is abundant literature on the extent of the initial diagnostic workup of the head 
and neck cancer patient to look for simultaneous primary tumours. However, very 
little is written about the follow-up examination of these patients. At present, most 
authors recommend annual chest roentgenograms in addition to regular physical 
examinations . This study shows that the regular follow-up visits have their greatest 
merit in the detection of second primary tumours located in the head and neck region, 
often helped by the fact that most of the patients at that time already developed 
symptoms . Also all esophageal second primary tumours as well as the majority of the 
lung tumours were diagnosed in an advanced stage of disease. Considering second 
primary lung tumours, yearly chest X-ray examination is clearly not sufficient as a 
screening for second primary lung tumours. This finding agrees with the findings of 
Engelen and with the disappointing results in general of population screening for lung 
cancer (23,24,25) . In a study performed by Rachmat et al. the value of twice yearly 
bronchoscopy and sputum cytology in the follow-up of patients with laryngeal cancer 
was evaluated. They concluded that it was not useful as a routine procedure (25). So 
the question remains bow frequently patients should be seen and how thorough the 
examinations should be at each follow-up visit. A logical approach would be to tailor 
the screening procedures in each individual case to the degree of risk for the 
development of second primary cancer. Early detection however, will be worthwhile 
only if effective treatment options exist for the tumours that are found. In case of a 
second primary tumour this is not always evident because of prior treatment of the 
index primary. Another method for influencing the survival of head and neck cancer 
patients is prevention of the development of a second cancer. It has been estimated 
that dietary and smoking habits contribute to at least 70% of all cancer deaths (26). 
Although smoking is a major risk factor in the development of initial primary cancer 
of the head and neck and the lung, it is still controversial whether stopping smoking 
once cancer is diagnosed affects the risk of second primary tumours (6,13 ,14,27 ,28). 
The occurrence of a second cancer early in follow-up suggests that the smoking and 
drinking habits of most patients prior to the appearance of the index tumour play a 
primary role in further tumour occurrence. The mucosa has been primed and retains 
a malignant potential (29,30) . Avoidance of tobacco and alcohol is however a 
73 
CHAPTER 6 : MULTIPLE PRIMARY MALIGNANT TIJMOURS IN PATIENTS 
desirable way to reduce the risk of second cancers of the aerodigestive system among 
long term survivors (28,31 ,32). Much research is currently being done to estimate the 
value of chemoprevention. Chemoprevention relies on the ability of certain chemical 
agents to block mutagenesis and control cellular differentiation and proliferation in 
epithelial tissues and therefore intervene in the process of carcinogenesis . Previous 
epidemiologic studies have linked the intake of certain micronutrients with a lower 
risk of cancer. Examples include vitamin E (alpha-tocopherol), beta carotene and 
vitamin A (33,34). Some experimental studies confirmed these findings . Gridley and 
Trickier showed that vitamin E supplementation may be effective in inhibiting oral 
cancer (35 ,36). A randomised trial of 13-cis retinoic acid in patients with oral 
leukoplakia revealed that it was able to cause significant decreases in the size of the 
leukoplakic lesions and to reverse dysplasia (13 ,34,37 ,38,39). In 1990, Hong et al. 
demonstrated that second primaries could be successfully prevented by the 
administration of 13-cis retinoic acid (6). Multi-institutional large-scale studies were 
started to investigate the use of different chemopreventive agents in the prevention of 
second primary cancers in patients treated for head and neck and/or lung cancer 
(6;1.7 ,34,40,41) .  Retinoids, which include natural vitamin A (retinol) and its esters 
and synthetic analogues, are the best studied class of agents in chemoprevention. In 
head and neck cancer, the clinical phase m trials in chemoprevention of second 
primary tumours have shown discordant results related to the type of retinoic acid. 
The results of the "Alpha-Tocopherol, Beta carotene Lung Cancer Prevention Trial" ,  
where a daily supplementation with placebo, alpha-tocopherol, beta carotene or both 
was given to a population of male smokers as a prevention trial, showed no reduction 
in the incidence of lung cancer among male smokers after five to eight years of 
dietary supplementation with alpha-tocopherol or beta carotene. The results of this 
study even raised the possibility that these substances may have harmful effects as 
they found an 1 8% increase in lung cancer in the group of male smokers who took 20 
mg of beta carotene daily for 5 to 8 years ( 42) . Also two large-scale American studies 
could show no beneficial effect of beta-carotene or the association of beta carotene 
with vitamin A in preventing cancer, cardiovascular mortality or any type of death 
(43). The investigators heading the beta carotene and retinol efficacy trial, known as 
CARET found a 28% increase in lung cancer in the group of participants taking a 
combination of beta carotene and vitamin A (43). This demonstrates that great care 
should be taken when interpreting results of epidemiological studies. Retinoids 
treatment should until now only be performed in control studies because of the 
toxicity at high doses. 
Helpful in both, early detection and chemoprevention of second primary tumours, 
would be the identification of high risk individuals. In the past decades attempt have 
been made to isolate subgroups of patients at high risk. Heavy smokers and drinkers, 
especially those who continue these habits after treatment of their index tumours have 
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been found to be at increased risk for the development of second primary cancers 
(28,32,40,44). In some studies it has been shown that the prevalence and the 
localisation of a second primary tumour depends on the site of the index tumour (45). 
In addition, some analyses showed that male sex was an additional risk factor for the 
development of a second primary (20,23). Other studies could not find a statistically 
significant effect of variables such as index site, tumour stage and age at index 
diagnosis in predicting the appearance of a second primary cancer (16,20). Besides 
the known exogenous risk factors like smoking and alcohol consumption, 
endogenous constitutional factors also play a role in the development of bead and 
neck cancer, since only a fraction of exposed individuals develops cancer (46,47 ,48). 
A positive family history for bead and neck cancer and/or lung cancer is an 
independent risk factor for the occurence of a squamous cell carcinoma in the upper 
aerodigestive tract (48). While it bas long been known that individuals with 
chromosome breakage syndromes are at increased cancer risk, evidence has been 
accumulating that cells derived from individuals developing some cancers exhibit 
increased radiation or mutagen sensitivity as detected by the G2 phase chromosome 
breakage assay when compared to cells derived from control individuals not bearing 
cancer (49,50). Mutagen sensitivity (defined as the mean number of breaks per cell 
{b/c) possibly reflects an individual's sensitivity for DNA damaging agents . 
Moreover, it has been shown that individuals who develop multiple bead and neck 
primaries demonstrate the greatest degree of mutagen sensitivity in their lymphocytes 
(47). Intrinsic susceptibility and exposure to carcinogens increase cancer risk in a 
dose dependent and interactive pattern (5 1 ,52,53). Therefore, to investigate cancer 
susceptibility, classical epidemiology using only environmental exposure data is no 
longer adequate and requires the incorporation of endogenous constitutional factors. 
Chromosome breakage assay might therefore be of use in identifying these high-risk 
individuals (47 ,54). Mutagen sensitivity in combination with smoking history can be 
used to identify those patients at highest risk for the development of multiple primary 
tumors and who can be targeted for more intense follow-up, behavioral interventions 
and cbemoprevention studies (55,56) . Different biomarkers are studied for their 
usefulness as markers for the prediction of second primary tumours. Some studies 
have shown that aberrant p53 oncoprotein expression seems to be an early event in 
the multistage process of head and neck multiple carcinogenesis and its expression in 
normal epithelium from head and neck cancer patients would indicate an increased 
risk for transformation to second primary cancer (57 ,58,59,60). Biomarkers which 
can be obtained with non-invasive techniques, would be of great value in screening 
and prevention in head and neck cancer patients . Biomarkers could also act as 
intermediate endpoints and would undoubtedly reduce time and cost currently 
required to conduct chemoprevention trials. 
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The best potential marker in exfoliated cells of the mucosa appears to be the histo­
blood group antigen H type 2-chain. At the serum level Cyfra 21-1  is of possible 
value for monitoring response to therapy in head and neck cancer patients and early 
detection of recurrent disease. But in both cases, long term follow-up studies are 
necessary to evaluate the predictive value for the development of second primary 
tumours (46). 
Future developments 
1 .  Better knowledge of individual risk factors for the development of second primary 
cancer 
2.  More effective screening programs especially for the detection of lung and 
esophageal cancer should be developed and evaluated in prospective studies . 
3 .  Further studies of potential early markers of carcinogenesis or establishing their 
value in predicting second primary cancer are necessary. 
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SUMMARY AND CONCLUSIONS 
The head and neck oncologists seem to be facing a complication with their success. 
Although an important reduction in local and regional relapses has been achieved, 
survival has not significantly increased during the last years. The occurrence of 
second primary tumours are partially responsible for this. In recent years, many 
reports were published reporting varying incidences of multiple primary tumours. 
Because most studies had only a limited number of patients, interesting observations 
were often not statistically significant. Therefore, an extensive review was performed 
on data from 25 studies reporting synchronous and metachronous second 
malignancies in head and neck cancer. This enabled us to have a better idea of the 
magnitude of the problem and to draw some statistically significant conclusions. 
Based on these 25 reports, we found an overall prevalence of multiple primary 
tumours of 15.2%, which suggest a sufficient large yield to make screening 
worthwhile.  Prospective studies showed a higher prevalence than retrospective 
studies . The prevalence and the localisation of second malignant tumours depended 
on the site of the index tumour. Oral cavity cancer showed the highest prevalence of 
second malignant tumours. Head and neck second primaries were most common in 
this group. Laryngeal cancer patients carried the highest risk for the development of 
a second primary in the lung. About half of the second primaries were detected within 
two years after the detection of the index tumour but they continued to appear even 
after 5 years. Second malignant neoplasms unquestionably influenced subsequent 
survival adversely. Possible improvement of the long-term survival of patients with 
squamous cell carcinoma of the head and neck could be achieved by more active 
control of second primary cancers . Several reports therefore recommended a more 
systematic search for additional primary lesions in all patients with newly diagnosed 
head and neck. As such, panendoscopy has been proposed by many investigators to 
search for simultaneous second primary malignant neoplasms in patients presenting 
with head and neck cancer. 
To evaluate the usefulness of this procedure in a Belgian population with head and 
neck cancer, we conducted a prospective study of patients with head and neck 
malignancies undergoing treatment and follow-up at the Department of 
Otorhinolaryngology at the University Hospital of Ghent. During 24 months, every 
new, untreated head and neck cancer patients was entered in the study. We used 
standardised forms to gain information about tobacco and alcohol use at the time of 
diagnosis, the medical history concerning previous malignancies and the delay in 
referral. We performed a panendoscopic examination as a routine screening 
procedure at the initial evaluation of every head and neck cancer patient. More than 
half of the patients consulted our institution with an advanced stage of disease which 
shows a possible bias of the cancer population we see at the University Hospital. 
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Concerning nicotine and alcohol use, our results supported the hypothesis that 
tobacco smoking is more strongly associated with lesions in sites heavily exposed to 
inhaled smoke, whereas alcohol consumption has a stronger effect on structures 
belonging to the «food channel» and reservoir systems. Interestingly enough, we 
found a lack of association between delay of diagnosis and tumour stage at diagnosis. 
We found however a statistical significant correlation between the delay and the 
tumour site. Therefore we concluded that tumour stage at diagnosis is determined 
mostly by the intrinsic difference in tumour aggressiveness and not so much by the 
delay in diagnosis. The delay reflects the clinical phase of the tumour which varies 
from site to site rather than it reflects the behaviour of the patient. 
Screening for simultaneous second primary tumours by means of the panendoscopy 
yielded an incidence of 3 .4% of simultaneous second primary neoplasms. This is 
consistent with findings reported from the Netherlands but low compared to other 
series deriving mostly from the United States. This can partially be explained by a 
different way of collecting data, but possibly also confirms racial and environmental 
differences. Because of the low yield we do not support the use of panendoscopy as 
it is described in chapter 3,  as a screenings procedure in every head and neck cancer 
patient. Concerning the esophagoscopy, there was no convincing evidence that 
esophageal screening during initial workup of head and neck cancer patients leaded 
to diagnosing smaller tumours with subsequent better survival rates. For the rigid 
bronchoscopy with bronchial washings as a screening procedure during the initial 
evaluation of a head and neck cancer patients, the same conclusions could be drawn. 
The incidence of simultaneous primary lung carcinomas was low and the sensitivity 
and specificity of the rigid bronchoscope too low to justify its use. Contamination of 
bronchial washings with tumour cells from the head and neck index tumour, limited 
seriously the usefulness of bronchial cytology. We supported only oro-hypopharyngo­
laryngoscopy under general anesthesia as a screening procedure for evaluation of the 
entire mucosa of the oral cavity, oropharynx, hypopharynx and larynx in every patient 
with a squamous cell carcinoma of the head and neck, this based on the fact that, 
although the incidence of simultaneous primary cancers was low, the majority of the 
simultaneous primary tumours were located in the head and neck region. 
There is abundant literature on the extent of the initial diagnostic workup of the head 
and neck cancer patient. However, very little is written about the follow-up 
examination of these patients . At our department, follow-up visits were performed 
every three months. As a screening procedure for second primary tumours, we 
performed a thorough clinical examination of the upper aero-digestive tract every 
three months. Every year, a standard X-ray of the chest was taken. We did not 
routinely perform flexible esophagoscopy or bronchoscopy. We specifically looked 
for recurrence of the index tumour and the appearance of second primary tumours in 
the upper aero-digestive tract and the lung. 
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As a result of a minimum follow-up of 24 months, we found an incidence of 13 .5% 
of second primary neoplasms, either simultaneously (3.%), synchronously (5.5%) or 
metachronously (8%). The most frequent sites of development of second malignant 
tumours were the lung and the head and neck region followed by cervical esophageal 
cancer. In the course of follow-up, we saw a continuing risk of new primary tumours 
following initial treatment. Our study suggested that the impact of a second primary 
cancer on survival equalled that of a recurrence of the primary tumour. The outcome 
is often worse than the corresponding index tumours because second primary tumours 
arise frequently in bad sites , such as the lung and the esophagus or in previously 
irradiated or operated areas. This study showed that the regular follow-up visits had 
their greatest merit in detection of second primary tumours located in the head and 
neck region, often helped by the fact that most of the patients at that time already 
developed symptoms. Yearly chest X-ray examination is clearly not sufficient as a 
screening for second primary lung tumours . This finding agrees with the 
disappointing results in general of population screening for lung cancer. 
Future directions 
Early detection and prevention strategies appear at present, the best options to reduce 
morbidity and mortality related to multiple primary cancer. 
For early detection of second primary cancers, more effective screening programs 
should be developed. Further efforts should be made to identify high risk individuals 
where more intense screening using more sensitive methods could have a higher 
yield. Up to date, our knowledge of risk factors is still fragmentary. Epidemiological 
studies could not find a statistically significant effect of variables as site or stage of 
the index tumour in predicting the appearance of a second primary cancer. The only 
patients who seem to be at low risk are those who did not smoke nor drink alcohol at 
the time of the first primary. Recent studies have shown that besides the known 
exogenous risk factors like smoking and alcohol consumption, endogenous 
constitutional factors play a role in the development of head and neck cancer. There 
is a genetically determined variability of enzyme systems important in the 
detoxification pathways of procarcinogenic components . Moreover, increased 
mutagen sensitivity shown in patients developing multiple primary tumours , could 
result from an inherited predisposition. Combination of exogenous and endogenous 
risk factors could lead to a selection of patients who will benifit most from cancer 
prevention and control. 
A valuable tool in monitoring squamous cell carcinoma of the head and neck would 
be the development of tissue (mucosa) markers. A suitable biomarker has to meet 
several criteria. It has to be detectable in tissue samples that can easily and repeatedly 
be obtained from several sites of the aerodigestive tract in a non-invasive way. The 
best potential marker in exfoliated cells of the mucosa appears to be the histo-blood 
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group antigen H type 2-chain. At the serum level Cyfra 21-1  looks to be of potential 
value for monitoring head and neck cancer patients . But in both cases, long term 
follow-up studies are necessary to evaluate the predictive value for the development 
of second primary tumours. 
Prevention of the development of a second cancer is a desirable objective. Dietary 
and smoking habits contribute to at least 70% of all cancer deaths . Although smoking 
is a major risk factor in the development of initial primary cancer of the head and 
neck, it is still controversial whether stopping smoking once cancer is diagnosed 
affects the risk of second primary tumours. The occurrence of second cancer early in 
follow-up suggests that the smoking and drinking habits of most patients prior to the 
appearance of the index tumour play a primary role in further tumour occurrence. 
Continuing efforts should however be made to motivate the patients to stop smoking 
and drinking, certainly in patients with a good prognosis. 
Much research is currently being done to estimate the value of chemoprevention as 
an additional approach to improve the life expectation of patients with squamous cell 
carcinoma of the head and neck. Two drugs are momentarily intensively studied: the 
retinoids and N-Acetylcystein (NAC). Both have an antioxidant activity. It has 
already been shown that the use of high-dose isotretinoin is able to reduce 
leukoplakia and to prevent the development of second cancers. NAC is still an object 
of clinical research. Biomarkers could be of value in monitoring and evaluating the 
efficacy of chemopreventive agents and they could serve as intermediate endpoints. 
Continuing efforts should be made to improve the understanding of the molecular 
events of the carcinogenesis process . The physician, engaged in the care of patients 
with cancer of the head and neck should be familiar with the concept of 
multicentricity. Careful vigilance should be exercised during the initial work-up and 
the follow-up period, not only for detecting recurrence but also to identify new 
primary cancers . 
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SAMENVATTING EN CONCLUSIES 
Alhoewel we de laatste jaren een belangrijke vooruitgang bebben geboekt in de 
bebandeling van plaveiselcelcarcinomen uitgaande van bet slijmvlies in bet boofd­
bals gebied, weerspiegelt zicb dat niet meteen in een verbetering van de overleving 
van deze patienten. De ontwikkeling van tweede primaire tumoren is hiervoor deels 
verantwoordelijk. Om een beter inzicbt te krijgen in de omvang van bet probleem 
bebben we een meta-analyse verricbt van data van 25 studies die in de loop der jaren 
zijn verscbenen over synchrone en metachrone tweede primaire tumoren. De 
prevalentie van multipele primaire tumoren was 15.2%. Zoals verwacht vonden we 
een hogere prevalentie in de prospectieve studies. De prevalentie en de lokalisatie van 
de tweede primaire tumor is afhankelijk van de localisatie van de index tumor. De 
boogste prevalentie werd gezien bij kanker van de mondholte. In deze groep was de 
voorkeurslokalizatie van de tweede primaire tumor in bet boofd-bals gebied. 
Patienten met larynx kanker lopen bet grootste risiko om een tweede tumor te 
ontwikkelen in de long. Ongeveer de helft van de tweede primaire tumoren wordt 
gedetecteerd in de eerste twee jaar na de detectie van de index tumor. We bemerken 
ecbter dat zij met een relatief constante frequentie ook jaren na detectie en 
bebandeling van de eerste tumor blijven voorkomen. Tweede primaire tumoren 
hebben over bet algemeen een slecbte prognose omdat zij ofwel op ongunstige 
plaatsen voorkomen (long en slokdarm), of in reeds behandeld gebied. Vroege 
detectie is een mogelijke optie ter vermindering van de morbiditeit en mortaliteit door 
tweede primaire tumoren. In die optiek is panendoscopie als screeningsmethode naar 
simultaan tweede primaire tumoren door veel auteurs geadviseerd gedurende de 
initiele evaluatie van een patient met een boofd en hals tumor. Om een idee te krijgen 
over de incidentie van tweede primaire tumoren in onze populatie en panendoscopie 
te evalueren als screeningsmethode, werd er in Oktober 1 990 gestart met een 
prospectief onderzoek bij patienten met boofd en hals tumoren. Gedurende 24 
maanden werd elke patient met een onbehandelde tumor van bet slijmvlies van bet 
boofd-hals gebied, in de studie ingebracht. Er werd gebruik gemaakt van een 
gestandaardiseerd computerdossier (cfr addendum) om rookgewoonten en 
alcoholgebruik te registreren, de diagnose en behandeling van de index tumor te 
registreren en de follow-up van deze patienten bij te houden. Wat betreft bet nicotine 
en alcohol gebruik in relatie tot de index tumor konden we besluiten dat bet roken 
vooral is geassocieerd met letsels in die gebieden die sterk zijn blootgesteld aan de 
sigaretterook, terwijl bet drinken van alcohol een sterker effect heeft op de 
voedselweg. Er was geen associatie tussen de periode van ontstaan van de klachten 
en de uiteindelijke diagnose («delay») en bet stadium van de tumor. Er was wei een 
statistisch significante correlatie tussen bet «delay» en de localisatie van de index 
tumor. Dit resultaat ondersteunt de hypothese dat bet stadium van de tumor op bet 
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moment van de diagnose vooral wordt bepaald door de intrinsieke biologische 
eigenschappen van de tumor, eerder dan dat deze bet gedrag van de patient 
weerspiegeld. De incidentie van simultaan primaire tumoren in onze populatie 
bedroeg 3 .4% . Dit is beduidend lager dan incidentie cijfers die we terugvinden in 
studies uit de Verenigde Staten. Dit kan deels te wijten zijn aan methodologische 
verschillen, maar reftecteert vermoedelijk ook raciale en omgevingsgebonden 
verschillen. Omwille van de lage incidentie in onze populatie, vinden wij bet 
screenen d.m.v. een panendoscopie zoals we die hebben beschreven, bij elke patient 
met een hoofd-hals tumor, niet zinvol. De incidentie van simultane longtumoren is 
laag. Daarbij komt nog dat de gevoeligheid van de rigide bronchoscopie met 
bronchiale washing laag is.  Gebaseerd op de vaststelling dat de meerderheid van de 
simultaan primaire tumoren gelokaliseerd zijn in bet hoofd-hals gebied, adviseren 
wij ,  bij de initiele evaluatie van een patient met een tumor in bet hoofd-hals gebied, 
enkel een oro-hypopharyngoscopie. Dit niet aileen ter evaluatie van de index tumor 
maar als screeningsmethode voor detectie van simultane primaire tumoren. 
Na de diagnose en de behandeling van de index tumor, werden de patienten 3-
maandelijks terug gezien op controleraadpleging. Elk jaar werd een thorax foto 
aangevraagd. Er gebeeurde verden geen screening d.m.v. bronchoscopie of 
oesophagoscopie. Na een minimum follow-up van 24 maanden, vonden we een 
incidentie van 135% van multipele primaire tumoren, waarvan 3% simultaan 
optraden, 5.5% synchroon en 8% metachroon. De tweede primaire tumoren waren bet 
meest frekwent gelokalizeerd in de long en de hoofd-hals regio. Het verschijnen van 
een tweede primaire tumor was even nefast voor de overleving als bet ontwikkelen 
van een recidief. Deze studie toonde ook aan dat een jaarlijkse thoraxfoto niet voldoet 
als screening naar tweede primaire tumoren in de long. 
Toekomstperspectieven 
Vroege detectie en preventie lijken op dit ogenblik de beste opties om de morbiditeit 
en de mortaliteit van tweede primaire tumoren in te dijken. 
Voor vroege detectie is de ontwikkeling van een meer efficient screeningsprogramma 
noodzakelijk. De identificatie van individuen die een boger risico lopen op de 
ontwikkeling van tweede primaire tumoren kan hierbij helpen. 
Voor vroege detectie is de ontwikkeling van een meer efficient screeningsprogramma 
noodzakelijk. De identificatie van individuen die een boger risico lopen op de 
ontwikkeling van tweede primaire tumoren kan hierbij helpen. 
Tot op heden is onze kennis over risicofactoren nog onvolledig. In epiderniologische 
studies kon geen statistisch significant effect worden aangetoond van variabelen zoals 
lokalisatie of stadium van de index tumor of de incidentie van een tweede primaire 
tumor. De enige patienten die blijkbaar een laag risico lopen zijn deze met een blanco 
nicotine en alcohol gebruik, op bet ogenblik van detectie van de eerste primaire 
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tumor. Recente studies bebben aangetoond dat naast de bekende exogene 
risicofactoren zoals roken en alcobolmisbruik, ook endogene constitutionele factoreD 
een rol kunnen spelen in de ontwikkeling van een boofd en halstumor. Er bestaat een 
genetisch bepaalde variabiliteit van enzymesystemen die belangrijk zijn in de 
detoxificatie processen van procarcinogene componenten. Daarenboven is 
aangetoond dat een gestegen mutagene gevoeligbeid in patienten met multipele 
primaire tumoren vaak erfelijk bepaald is. Een combinatie van exogene en endogene 
risicofactoren kan ons belpen bij de selectie van patienten waar intensief zal moeten 
worden gescreend naar bet ontwikkelen van tweede primaire tumoren. 
Een belangrijk hulpmiddel in bet monitoren van epidermo'ide epitheliomata van het 
neus-, keel- en oorgebied zou de ontwikkeling kunnen zijn van mucosale 
weefselmerkers. Een bruikbare biologiscbe merker moet aan verscbillende 
voorwaarden voldoen. Hij dient detecteerbaar te zijn in weefselspecimen die 
makkelijk en berhaaldelijk kunnen worden afgenomen van verschillende lokalisaties 
in de aerodigestieve tractus op een niet-invasieve manier. De beste merker in 
mucosale cellen lijkt de bloedgroep antigen H- type 2. In bet serum lijkt Cyfra 21-1  
potentiele waarde te bebben om patienten met een boofd-en halstumor te volgen. In 
beide gevallen ecbter zijn lange termijnstudies noodzakelijk om de predictieve 
waarde van deze merkers te bepalen in het kader van tweede primaire tumoren. 
Een belangrijk objectief is de preventie van ontwikkeling van tweede primaire 
tumoren. Het is bekend dat voedings- en rookgewoonten een inbreng bebben in 
minstens 70% van aile overlijdens door kanker. Alhoewel het is aangetoond dat roken 
een belangrijke risicofactor is in bet ontwikkelen van een plaveiselcelcarcinoom in 
bet hoofd- en balsgebied, bestaat er nog steeds controverse over de vraag of het 
stoppen met roken een invloed beeft op bet risico om een tweede primaire tumor te 
ontwikkelen. Het optreden van tweede primaire tumoren kort na bet ontwikkelen van 
de eerste suggereert dat rook-en drinkgewoonten v66r bet ontstaan van de indextumor 
een belangrijke rol spelen in de ontwikkeling van een latere tumor. Volgebouden 
inspanningen om de patienten te motiveren te stoppen met roken en drinken van 
alcohol is uiteraard van bet allergrootste belang ; zeker bij patienten met een goede 
prognose na een eerste tumor. 
Momenteel wordt er veel onderzoek gedaan rood de waarde van chemopreventie als 
een aanvullende benadering om de levensverwachting bij patienten met epidermo'ide 
epitheliomata van het neus-, keel-, oorgebied te verbeteren. 1\vee medicaties worden 
momenteel grondig bestudeerd : de retino'iden en N-Acetylcystefue (NAC). Beiden 
hebben anti-oxiderende activiteit. Vroeger werd reeds aangetoond dat bet toedienen 
van hoge dosissen synthetisch vitamine A in staat is om leukoplakiiscbe letsels te 
reduceren en om ontwikkeling van tweede tumoren tegen te gaan. De activiteit van 
NAC wordt nu nog klinisch onderzocht. Biologische merkers kunnen een waarde 
hebben in bet monitoren en bet evalueren van bet nut van chemopreventie. 
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Het is van het allergrootste belang nog meer inzicht te verwerven in de moleculaire 
processen die tijdens de carcinogenese plaatsvinden. De arts die te maken heeft met 
patienten met een hoofd-en halstumor moet vertrouwd zijn met het concept van 
multi-centriciteit. Tijdens de initiele diagnostische oppuntstelling en tijdens de 
follow-up dient hij niet aileen zorgvuldig recidieven op te sporen maar ook bedacht 
te zijn op de ontwikkeling van secundaire primaire tumoren. 
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Data file used for the registration and follow-up of head and neck cancer patients in this 
study. 
HOOFD- HALS ONCOLOGIE REGISTRATIE 
PERSOONLUKE GEGEVENS 
Naarn : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Voomaarn : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Straat + n• : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Woonplaats : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Postn : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Telefoon : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Burg. Stand : 
Naam echtgenoot : 
Geboortedatum : . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Adremanummer : . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 




D Follow up onderzoek : kliniek 
D Follow up onderzoek : Rx 
D Follow up onderzoek : labo 




Localisatie : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Ras : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 




Verwijzende arts : . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Huisarts : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Behandelende arts : . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Afdeling : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Indien stageringsonderzoek pos. : 
D trachea-bronchoscopie 









TOPOGRAFIE EERDERE TUMOREN : 
Topografie : 
Tumor 1 :  
Tumor 2 :  
Tumor 3 :  











0 sigaretten zonder 
filter 
0 sigaretten met filter 
0 onbekend 
D gestopt sinds > 2 jaar 
0 gestopt sinds > 1 jaar 
0 gestopt sinds < 1 jaar 
D niet gestopt 
% 
Jaartal : 
Duur van de klacht : 
Topografie 
D geen klachten 
D 0-3 maanden 
D 4-6 maanden 
D 7-12 maanden 
D 12 maanden 
D onbekend 
Code 
Rookgewoontes sigaretten detail : 
0 < 10 pack year 
0 10-20 pack year 
0 20-30 pack year 




D niet dagelijks 
D 1 Eldag 
D 2-4 Eldag 
D 5-9 Eldag 
D 9 Eidag 
D onbekend 
ANAMNESE II 
Andere Riscofactoren : 
D geen 
D slechte mondhygiene 
D na bestraling H.& Neck. 
D Ebstein Barr virus + 
D Precancerose 
D afweerstoornis 
D Auto lmmuunziekte 
D andere 
TUMOR ANAMNESE I 
Alcoholstop : 
D gestopt sinds > 2 j. 
D gestopt sinds > 1 j. 
D gestopt sinds < 1 j. 
Indien precancerose : 
Mondholte + oesophagus : 
D leukoplakie homogene type 
D leukoplakie nodulaire type 
D erythroplakie 
D lichten planus 
Larynx :  
D dysplasie : graad I 
D dysplasie : graad II 
Incidentiedatum : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Diagnose gesteld door : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Is er eeen stageringsonderzoek verricht ? 





D ja D nee 
0 onderzoek mondholte 
D nasopharyngoscopie 
D halspalpatie 
Complicatie bij stageringsonderzoek : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
PRIMAIRE TUMOR : 
Tumorlocalisatie : . . .  . .  . .  . . .  . .  . .  . .  . .  . . .  . .  . .  . .  . .  . .  . .  Unifocaal/multifocaal : . . . . . . . . . . . . . . . . . . . .  . 
Links/Rinchts : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ontsteking!Randreactie : . . . . . . . . . . . . . . . . .  . 
Voor/Achter : . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . .  lnfiltratie : D infiltraties in bot 
Maximale doorsnede van de Turner : . . . . . . . . . . . .  em. 
D infiltraties in spier 
D infiltraties in huid 
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ADDENDUM 
REGIONALE LYMFEKLIEREN : 
Lymfeklieren palpapel : D ja 0 nee in level : 0 Level I 
0 Level 2 
0 Level 3 
D Level 4 
0 Level 5 
D Level 6 
Afmeting grootste klier : . . . . . . . . .  em. 
Metastasen op Afstand : 
metastasen : D geen 
D in de long 
D elders 
D in de long en elders 
D onbekend 
















. .  
_ 










. .  
_ 








. .  _ . . 
_ 
. .  
_ 
. .  
_ 





IDSTOLOGIE PRIMAIRE TUMOR 
Morfologisch type : 
0 Plaveiselcelcarcinoom 
0 Adenocarcinoom 
0 Verruceus carcinoom 
0 Verruceus carcinoom 





0 Anaplastische tumor 
0 andere 
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Dift'erentiatie graad : 
D Goed gedifferentieerd (Graad I) 
D Matig gedifferentieerd (Graad II) 
D Slecht gedifferentieerd (Graad III) 
0 Differentiatie niet gespecificeerd 
Extensie : (insitu/invasieflmetastase) 
0 Benigne 
D Maligne primaire tumor 
0 Maligne metastase of secundaire locatie 
D Maligne (onzeker:primaire tumor of metastase) 
D dysplasie graad I 
0 dysplasie graad II 
D dysplasie graad m 
ADDENDUM 
Maximale doorsnede : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Groeiwijze : 
radicaliteit : 
Infiltratie diepte : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Unifocaal/Multifocaal : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Ontstekingsreactie : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
IDSTOLOGIE REGIONALE LYMFEKLIEREN 
Afmeting grootste lyrnfeklier : . . . . . . . . . . . .  em 
Kapseldoorbraak : 0 geen kapseldoorbraak 
0 kapseldoorgroei rechts 
0 kapseldoorgroei links 
0 kapelsdoorgroei beiderzijds 
0 onbekend 
onderzocht tumorpositief onderzocht tumorpositief 
Level l . . . . . . . . . . . . . . .  
Level 2 . . . . . . . . . . . . . . .  
Level 3 . . . . . . . . . . . . . . .  
Level 4 . . . . . . . . . . . . . . .  
Level S · · · · · · · · · · · · · · ·  
Level 6 . . . . . . . . . . . . . . .  
THERAPIE I 
Therapie Opzet : 




. . . . . . . . . . . . . . . . . . 
· · · · · · · · · · · · · · · · · ·  
· · · · · · · · · · · · · · · · · ·  
. . . . . . . . . . . . . . . . . .  
· · · · · · · · · · · · · · · · · ·  







Initiele therapievolgorde : (binnen 3 
maanden) 















OPERATIEVE BEHANDELING PRIMAIRE TUMOR : 
Soort Operatie : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Macroscopisch radicaal : . . . . . . . . . . . . . . . . . . . .  . 
Aanvullende resectie nodig ? 0 ja 
0 niet 
nodig 
Datum opera tie : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Reconstructie : 
0 Directe sluiting 
0 Huidtransplantaties 
0 Transpositielap huid 
D Transpositielap mucosa 
0 Gesteelde lap myocutaan 
0 Gesteelde spierlap 
D Vrije lap 
0 Onbekend 
OPERATIEVE BEHANDELING LYMFEKLIEREN : 
Recbts 
Datum : 
Type dissectie : 
0 geen nekdissectie 
0 radicale nekdissectie 
0 gemodifieerd radicale nek dissectie 
0 supra omohyoidale nekdissectie 
0 posterolaterale nek dissectie 
0 laterale nek dissectie 
0 dissectie vh voorste nek compartiment 
0 uitgebreide radicale nekdissectie 
0 onbekend 
RADIOTIIERAPIE : 
Startdatum : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Aantal Gray op tumor : . . . . . . . . . . . . . . . . . . . . . .  . .  
Aantal Gray op hals : . . . . . . . . . . . . . . . . . . . . . . . . . . . 
CHEMOTIIERAPIE : 
Opzet : 0 Inductie chemotherapie 
D Adjuvante chemotherapie 





Type dissectie : 
D geen nekdissectie 
D radicale nekdissectie 
0 gemodifieerd radicale nek dissectie 
0 supra omohyoidale nekdissectie 
D posterolaterale nek dissectie 
D laterale nek dissectie 
0 dissectie vh voorste nek compartiment 
D uitgebreide radicale nekdissectie 
D onbekend 
Stopdatum : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
stopdatum 
FOLLOW UP :  









Doodsoorzaak : 0 door tumor (primair) 
0 door tumor (secundair) 
0 door andere oorzaak 
Datum overlijden : . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Ontslagdatum eerste behandeling : 




VOLGENDE MALIGNITEIT : 
lncidentite datum : . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . 
Topografie (ICD-0*) : 
Histologie (ICD-0*) : 
Rookgewoontes : D gestopt sinds detectie primaire tumor 
Rookgewoontes : D gestopt sinds detectie primaire tumor 
D ongewijzigd (cfr prim. tumor) 
D > de helft venninderd sinds detectie primaire tumor 
Alcoholgebmik : D gestopt sinds detectie primaire tumor 
D ongewijzigd (cfr prim. tumor) 
D > de helft venninderd sinds detectie primaire tumor 
OPMERKINGEN : 
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